{"gene":"CCL5","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1988,"finding":"CCL5 (RANTES) was identified as a novel T cell-specific secreted molecule belonging to a new gene family of small proteins characterized by conserved cysteine residues; the gene product is predicted to be ~8 kDa after signal peptide cleavage with 4 cysteines and no N-linked glycosylation sites.","method":"cDNA library screening, sequence analysis, Northern blot","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — original cloning and characterization paper, foundational discovery, highly cited","pmids":["2456327"],"is_preprint":false},{"year":1990,"finding":"CCL5/RANTES protein selectively attracts human blood monocytes and CD4+/UCHL1+ memory T lymphocytes but not naive T cells, demonstrating chemokine activity for specific leukocyte subsets.","method":"Chemotaxis assay with purified/recombinant RANTES, flow cytometry cell phenotyping","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro functional assay, foundational paper with >1300 citations","pmids":["1699135"],"is_preprint":false},{"year":1992,"finding":"CCL5/RANTES released by thrombin-stimulated platelets is a potent eosinophil chemoattractant; purification revealed two natural forms: a full-length form (EoCP-2, ~7,863 Da, with methionine oxidation) and an O-glycosylated form (EoCP-1, ~8,355 Da), both with ED50 ~2 nM for eosinophil chemotaxis.","method":"HPLC purification, NH2-terminal sequencing, electrospray mass spectrometry, eosinophil chemotaxis assay","journal":"Journal of Experimental Medicine","confidence":"High","confidence_rationale":"Tier 1 — purification to homogeneity, mass spectrometry, direct functional assay, replicated with recombinant material","pmids":["1380064"],"is_preprint":false},{"year":1993,"finding":"The RANTES/CCL5 gene spans ~7.1 kb, is composed of 3 exons (133, 112, and 1075 bases) and 2 introns, with conserved intron/exon boundaries relative to other CC chemokines. The ~1 kb promoter contains consensus elements for T cell/hematopoietic, myeloid, and ubiquitous transcription factors; promoter activity is cell-type specific (high in mature T cells and erythroleukemic cells, absent in early T cell lines).","method":"Genomic cloning, promoter-luciferase reporter assays, deletion analysis","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 1 — direct functional promoter mapping with multiple deletion constructs in multiple cell lines","pmids":["7689610"],"is_preprint":false},{"year":1995,"finding":"CCL5/RANTES (together with MIP-1α and MIP-1β) was identified as a major HIV-suppressive factor produced by CD8+ T cells; recombinant CCL5 dose-dependently inhibited HIV-1, HIV-2, and SIV, and combination neutralizing antibodies against all three chemokines abrogated CD8+ T cell HIV-suppressive activity.","method":"Protein purification from CD8+ T cell supernatants, N-terminal sequencing, neutralizing antibody blockade, HIV replication assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — purification, sequencing, and functional neutralization, foundational paper with >2500 citations","pmids":["8525373"],"is_preprint":false},{"year":1996,"finding":"Retention of the initiating methionine (Met-RANTES) completely abolishes CCL5 agonist activity in calcium mobilization and chemotaxis assays while producing a potent selective antagonist of both RANTES and MIP-1α through competition for their shared receptor CC-CKR-1, demonstrating that the integrity of the amino terminus is critical for receptor activation.","method":"Recombinant protein expression in E. coli, calcium flux assay, chemotaxis assay, radioligand competition binding on THP-1 cells and transfected HEK cells","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with mutagenesis, multiple orthogonal assays, highly cited","pmids":["8576227"],"is_preprint":false},{"year":1996,"finding":"CCL5/RANTES blocks HIV-1 entry into cells through a pertussis toxin-insensitive mechanism; the V3 domain of gp120 is a critical determinant of susceptibility to CCL5-mediated HIV suppression, linking CCR5 co-receptor usage to chemokine-mediated blocking.","method":"HIV infection assay, pertussis toxin treatment, chimeric V3 domain constructs","journal":"Nature Medicine","confidence":"High","confidence_rationale":"Tier 1 — mechanistic virology experiments with V3 domain mutants and entry-stage analysis","pmids":["8898753"],"is_preprint":false},{"year":1996,"finding":"CCR5 was molecularly cloned as the high-affinity G protein-coupled receptor for CCL5/RANTES, MIP-1β, and MIP-1α on monocytes; receptor activation leads to inositol phosphate generation and calcium flux, both blocked by pertussis toxin, establishing CCR5 as a Gi-coupled receptor for CCL5.","method":"cDNA cloning, stable transfection, radioligand binding, calcium flux assay, pertussis toxin treatment","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — receptor cloning with binding and signaling characterization, replicated by multiple groups","pmids":["8663314","8699119"],"is_preprint":false},{"year":1998,"finding":"CCL5/RANTES induces a unique biphasic Ca2+ signal in T cells: the first phase is G-protein-mediated and chemotaxis-associated; the second phase (at >100 nM) is tyrosine kinase-linked, correlates with CD3 expression level, and is partially dependent on TCR co-stimulation, indicating a T cell activation pathway distinct from chemotaxis.","method":"Ca2+ flux assay, cell sorting by CD3 expression, anti-CD3 pre-stimulation experiments","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional signaling assay with genetic correlation, single lab","pmids":["9552000"],"is_preprint":false},{"year":1998,"finding":"CCL5-RANTES fusion antibody retains both CCR5-binding activity and chemoattractant function; the fusion protein induces actin polymerization in THP-1 cells, supports T cell transendothelial migration, and blocks HIV-1 CCR5-mediated entry, demonstrating that the functional domains of CCL5 can be preserved in fusion constructs.","method":"Flow cytometry, actin polymerization assay, transendothelial migration assay, HIV infection inhibition assay","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays demonstrating preserved CCL5 activity in fusion format","pmids":["9759898"],"is_preprint":false},{"year":1998,"finding":"CCL5/RANTES and other chemokines (SDF-1α, fractalkine) regulate Ca2+ signaling and reduce voltage-dependent Ca2+ currents and excitatory postsynaptic current frequency in hippocampal neurons, and protect neurons from gp120-induced apoptosis, establishing direct chemokine receptor signaling in CNS neurons.","method":"Fura-2 Ca imaging, whole-cell patch clamp, RT-PCR for receptor expression, apoptosis assay","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal electrophysiology and imaging methods, functionally validated","pmids":["9826729"],"is_preprint":false},{"year":2000,"finding":"RANTES/CCL5 expression in T lymphocytes is regulated 'late' (3–5 days post-activation) by RFLAT-1, a Krüppel-like family transcription factor whose expression is itself translationally regulated after T cell activation, providing a mechanism for the delayed kinetics of CCL5 expression.","method":"Promoter characterization, transcription factor identification, translational regulation assays","journal":"Immunological Reviews","confidence":"Medium","confidence_rationale":"Tier 2 — functional characterization of a novel transcriptional regulator, single lab with promoter and translational assays","pmids":["11138780"],"is_preprint":false},{"year":2001,"finding":"CCL5/RANTES secreted by thrombin-stimulated platelets is deposited on the surface of inflamed or atherosclerotic endothelium (requiring endothelial activation by IL-1β) and triggers shear-resistant monocyte arrest under flow conditions via RANTES receptors, as blocked by Met-RANTES or anti-RANTES antibody.","method":"Parallel-wall flow chamber, ELISA, immunofluorescence, ex vivo carotid artery perfusion, immunohistochemistry in apoE-/- mice","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in vitro and in vivo, mechanistic blockade experiments","pmids":["11282909"],"is_preprint":false},{"year":2001,"finding":"CCL5/RANTES activates Jak2 and Jak3 (pertussis toxin-insensitive), induces tyrosine phosphorylation of CCR5 and Src kinase p56lck (which associates with Jak3), and activates the p38 MAPK pathway (evidenced by p38 and MAPKAP kinase-2 phosphorylation) in CCR5-expressing T cells.","method":"Immunoprecipitation, Western blot for phosphorylation, pertussis toxin inhibition, pharmacological p38 inhibition","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple kinase targets identified with Co-IP and pharmacological inhibition, pertussis toxin controls","pmids":["11278738"],"is_preprint":false},{"year":2002,"finding":"CCL5/RANTES transcription in alveolar epithelial cells is controlled primarily through an NF-κB cis-element in the promoter after TNF-α stimulation; IFN-γ does not activate transcription but stabilizes RANTES mRNA. TNF-α induces nuclear translocation of IRF-3, but unlike viral infection, TNF-α-induced IRF-3 does not bind the RANTES ISRE, revealing stimulus-specific regulation.","method":"Promoter deletion/mutagenesis, luciferase reporter assay, EMSA, nuclear fractionation","journal":"American Journal of Physiology - Lung","confidence":"High","confidence_rationale":"Tier 1 — promoter deletion and mutagenesis with multiple orthogonal methods","pmids":["12388374"],"is_preprint":false},{"year":2003,"finding":"H. pylori induces RANTES/CCL5 transcription in gastric epithelial cells through NF-κB activation via IKK and NIK (not through TLR/MyD88 or MEK1 pathways); this requires an intact cag pathogenicity island, as shown by kinase-deficient IKK/NIK mutant transfection.","method":"Reporter gene assay, transfection of kinase-deficient mutants, coculture with H. pylori","journal":"Infection and Immunity","confidence":"High","confidence_rationale":"Tier 1 — dominant-negative mutagenesis with pathway dissection","pmids":["12819056"],"is_preprint":false},{"year":2003,"finding":"17β-estradiol (E2) inhibits NF-κB-dependent CCL5 transcription in keratinocytes by competing with the p65 subunit for limiting amounts of the coactivator CBP/CREB-binding protein, without affecting IκBα degradation or NF-κB DNA binding; both ERα and ERβ mediate this effect.","method":"Promoter-luciferase assay, EMSA, immunofluorescence, co-transfection with coactivators/receptor mutants","journal":"Journal of Investigative Dermatology","confidence":"High","confidence_rationale":"Tier 1 — mechanistic dissection of transcriptional inhibition with domain mapping, multiple orthogonal assays","pmids":["12603855"],"is_preprint":false},{"year":2004,"finding":"CCL5 heterophilic interactions with platelet factor 4 (PF4) require structural motifs important for CCL5 higher-order oligomerization (the tetrameric E26A mutant supports PF4 binding but not amplification of monocyte arrest); PF4-RANTES heterodimer formation amplifies RANTES-triggered shear-resistant monocyte arrest on endothelium and involves monocytic chondroitin sulfate.","method":"Surface plasmon resonance, ligand blot, flow chamber monocyte adhesion assay, RANTES oligomerization mutants","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — biophysical binding measurement plus functional mutagenesis studies","pmids":["15459010"],"is_preprint":false},{"year":2005,"finding":"Platelet microparticles (PMPs) contain substantial RANTES/CCL5 and serve as a transcellular delivery system, depositing RANTES on activated endothelium during transient rolling interactions in a flow-dependent manner; PMP-dependent RANTES deposition requires P-selectin, GPIb, GPIIb/IIIa, and JAM-A differentially, and promotes subsequent monocyte arrest.","method":"Flow chamber with video microscopy, blocking antibodies, genetic deficiency of PMP adhesion receptors, immunofluorescence","journal":"Arteriosclerosis, Thrombosis, and Vascular Biology","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection with multiple receptor knockouts and flow conditions","pmids":["15890969"],"is_preprint":false},{"year":2006,"finding":"CCL5-induced apoptosis in CCR5-expressing T cells requires: (1) GAG binding on the cell surface (exogenous heparin/chondroitin sulfate or GAG digestion prevents apoptosis; non-GAG-binding mutant 44AANA47-CCL5 does not induce apoptosis); (2) higher-order oligomerization (dimer-forming E66S mutant fails to induce apoptosis; tetramers are the minimal active aggregate); (3) CCR5 tyrosine 339 (CCR5Y339F cells are resistant). The mechanism involves cytochrome c release, caspase-9 and caspase-3 activation.","method":"T cell apoptosis assay, GAG digestion, exogenous GAG competition, CCL5 oligomerization mutants, CCR5 tyrosine mutant, caspase activation assays, cytochrome c release","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with mutagenesis of both ligand and receptor, multiple orthogonal readouts","pmids":["16807236"],"is_preprint":false},{"year":2006,"finding":"In vivo lung-specific CCL5 overexpression in transgenic mice preferentially induces neutrophil infiltration (rather than eosinophils), and upregulates expression of MIP-2, IP-10, and MCP-1 in the lung, demonstrating a role for CCL5 in neutrophil trafficking.","method":"Inducible transgenic mouse model, bronchoalveolar lavage, differential cell counts, RT-PCR","journal":"American Journal of Physiology - Lung","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo gain-of-function in transgenic mice with defined cellular phenotype","pmids":["11000125"],"is_preprint":false},{"year":2006,"finding":"CCL5-evoked Ca2+ elevation in human microglia via CCR5 requires Jak activity, inhibitory G protein (pertussis toxin-sensitive component), PI3K, Btk, and PLC-mediated IP3-dependent Ca2+ release from intracellular stores; the majority of the Ca2+ increase is derived from NAD metabolite-activated sources: cADPR releases Ca2+ from intracellular stores and ADPR evokes Ca2+ influx via nimodipine-sensitive channels.","method":"Fura-2 calcium imaging, pharmacological inhibitors (Jak inhibitor, PI3K inhibitor, BTK inhibitor, PLC inhibitor), pertussis toxin, nimodipine","journal":"Journal of Neuroscience Research","confidence":"High","confidence_rationale":"Tier 1 — systematic pharmacological dissection of signaling pathway with multiple inhibitors and calcium imaging","pmids":["16547971"],"is_preprint":false},{"year":2007,"finding":"The transcription factor KLF13 (RFLAT-1), together with NF-κB rel proteins p50/p65 and scaffolding proteins, forms a molecular enhancesome at the RANTES promoter in T lymphocytes that recruits chromatin-modifying enzymes (acetylation, methylation, phosphorylation), and KLF13 itself is translationally regulated to control the delayed (3–5 day) RANTES expression after T cell activation.","method":"Promoter analysis, transcription factor interaction studies, chromatin modification assays","journal":"Nature Clinical Practice Nephrology","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic complex characterization, though this is a review synthesizing primary findings","pmids":["17322928"],"is_preprint":false},{"year":2009,"finding":"JNK MAPK pathway controls constitutive CCL5 expression in peripheral blood NK cells (unlike delayed expression in T cells) through SP1 binding to a compact promoter region (-75 to -56 bp upstream of TSS), as shown by promoter-reporter assays, EMSA, ChIP, and site-directed mutagenesis of the SP1 binding site.","method":"Specific MAPK inhibitors, promoter-reporter assay, EMSA, ChIP, heterologous promoter constructs, site-directed mutagenesis","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods including mutagenesis and ChIP confirming SP1 as the key transcription factor","pmids":["19124744"],"is_preprint":false},{"year":2009,"finding":"CCL5 promotes macrophage survival in human adipose tissue by protecting macrophages from free cholesterol-induced apoptosis via activation of the Akt and Erk pathways, and triggers adhesion and transmigration of blood monocytes through endothelial cells of human adipose tissue.","method":"Monocyte transmigration assay, apoptosis assay with free cholesterol, Western blot for Akt/Erk phosphorylation","journal":"Arteriosclerosis, Thrombosis, and Vascular Biology","confidence":"Medium","confidence_rationale":"Tier 2 — functional assays with defined signaling readouts, single lab","pmids":["19893003"],"is_preprint":false},{"year":2010,"finding":"Endothelial CCL5 expression, induced by selectin-mediated tumor cell interactions, promotes monocyte recruitment to metastatic tumor cells; CCL5 receptor antagonist treatment during early metastasis reduced tumor cell survival and attenuated metastasis, establishing a mechanistic role for CCL5 in forming the metastatic microenvironment.","method":"Microarray, flow chamber monocyte recruitment assay, CCL5 receptor antagonist treatment, in vivo metastasis model","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — functional mechanistic studies in vitro and in vivo with antagonist, single lab","pmids":["19779041"],"is_preprint":false},{"year":2010,"finding":"CCL5 stimulates externalization of S100A4 protein via microparticle shedding from plasma membranes of tumor and stroma cells; conversely, released S100A4 induces fibronectin upregulation in fibroblasts and RANTES upregulation in tumor cells, establishing a positive feedback loop. In vivo, tumor-derived CCL5 promotes S100A4 release into circulation and increases metastatic burden.","method":"Microparticle shedding assay, cytokine induction assay, wound healing/migration assay, wild-type vs. S100A4-/- mouse models","journal":"PloS One","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic feedback loop established with in vitro and in vivo models","pmids":["20442771"],"is_preprint":false},{"year":2011,"finding":"CCL5 oligomers form rod-shaped, double-helical polymers; the E66 and E26 mutations that disrupt oligomerization are explained by the structural model. GAG binding by CCL5 oligomers uses a positively charged, fully exposed KKWVR motif (distinct from the partially buried BBXB motif used by monomers/dimers), providing a unified mechanism for how oligomerization and GAG binding cooperate in CCL5 function.","method":"NMR residual dipolar couplings, SAXS, hydroxyl radical footprinting, NMR cross-saturation, structural modeling","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — integrated structural approach with multiple orthogonal methods, functional mutant explanation","pmids":["21827949"],"is_preprint":false},{"year":2012,"finding":"CCL5 promotes osteosarcoma cell migration and upregulates αvβ3 integrin through CCR5 (not CCR1 or CCR3), activating a MEK→ERK→NF-κB signaling cascade; CCR5 mAb, siRNA, and specific inhibitors of MEK, ERK, and NF-κB all abolish CCL5-enhanced migration and integrin upregulation.","method":"Migration assay, flow cytometry (integrin expression), siRNA, pharmacological inhibitors, dominant-negative constructs","journal":"PloS One","confidence":"Medium","confidence_rationale":"Tier 2 — pathway dissection with siRNA and multiple pharmacological inhibitors, single lab","pmids":["22506069"],"is_preprint":false},{"year":2012,"finding":"CCL5-mediated angiogenesis in vitro and in vivo is dependent on both G protein-coupled receptors CCR1 and CCR5, and on heparan sulfate proteoglycans (syndecan-1, syndecan-4, CD44); chemokine oligomerization and GAG binding are both essential for pro-angiogenic effects, as oligomerization-deficient (E66A) and GAG-binding-deficient (44AANA47) mutants lose angiogenic activity. Pro-angiogenic signaling involves MMP-9 and VEGF secretion by endothelial cells.","method":"In vitro endothelial migration/tube formation, rat subcutaneous angiogenesis model, receptor-blocking antibodies, CCL5 oligomerization/GAG mutants, anti-VEGFR antibodies","journal":"Angiogenesis","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with in vitro and in vivo validation, multiple receptor blocking experiments","pmids":["22752444"],"is_preprint":false},{"year":2012,"finding":"CCL5/CCR5 interaction in chondrosarcoma cells activates PI3K→Akt→NF-κB signaling, leading to upregulation of MMP-3, which mediates increased cell migration; PI3K, Akt, and NF-κB inhibitors and MMP-3 siRNA all block CCL5-induced migration.","method":"Migration assay, MMP-3 siRNA/inhibitor, pharmacological inhibitors of PI3K/Akt/NF-κB, Western blot","journal":"Biochemical Pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — pathway dissection with siRNA and multiple inhibitors, single lab","pmids":["19682436"],"is_preprint":false},{"year":2014,"finding":"The Fli-1 transcription factor (Ets family member) drives CCL5 transcription by binding to Ets sites in the distal CCL5 promoter; Fli-1 transactivation is stronger than Ets1, and Ets1 acts as a dominant-negative. Systematic deletion of a 225-bp promoter region identifies critical Fli-1 binding sites; mutation of the Fli-1 DNA-binding domain reduces CCL5 promoter transactivation.","method":"Fli-1 siRNA knockdown, promoter-reporter assays, ChIP of endogenous Ets binding sites, deletion analysis, DNA-binding domain mutation","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 1 — ChIP, mutagenesis, and promoter reporter assays in multiple systems","pmids":["25098295"],"is_preprint":false},{"year":2014,"finding":"YB-1 phosphorylation at Ser-102 (mediated by Akt) increases its binding affinity and trans-activating capacity at the CCL5 promoter during early monocyte/macrophage differentiation; calcineurin (CN) subsequently dephosphorylates YB-1 at Ser-102, preventing CCL5 promoter binding, as demonstrated by Co-IP of YB-1/CN interaction and in vivo cyclosporine A effects on YB-1 phosphorylation status.","method":"Co-immunoprecipitation, Western blot for phospho-YB-1, promoter-reporter assay, calcineurin inhibitor (cyclosporine A) in vivo","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — Co-IP plus in vitro and in vivo functional validation with phospho-specific analysis","pmids":["24947514"],"is_preprint":false},{"year":2014,"finding":"Computational modeling of the CCL5:CCR5 complex structure reveals that both CCL5 and HIV-1 gp120 V3 loop primarily interact with the same CCR5 residues, providing structural insight into CCL5's mechanism of blocking HIV-1 entry via competitive occupation of the CCR5 binding interface.","method":"Computational free energy calculations and molecular dynamics simulations, validated against experimental mutagenesis data","journal":"Scientific Reports","confidence":"Low","confidence_rationale":"Tier 4 — computational prediction; experimental validation is indirect (consistency with published mutational data)","pmids":["24965094"],"is_preprint":false},{"year":2014,"finding":"IL-32θ downregulates CCL5 expression by interacting with PKCδ (shown by Co-IP and pulldown assay), facilitating PKCδ-mediated phosphorylation of STAT3 at Ser-727, which prevents STAT3 from binding to and transactivating the CCL5 promoter.","method":"Co-immunoprecipitation, pulldown assay, ELISA, promoter binding assay","journal":"Cellular Signalling","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP/pulldown with functional promoter analysis, single lab","pmids":["25280942"],"is_preprint":false},{"year":2015,"finding":"CCL5 interactions with chondroitin sulfate hexasaccharides involve both the BBXB motif in the 40s loop and residues in the N-loop (similar to receptor N-terminus interactions); the binding orientation is highly dependent on sulfation pattern of N-acetyl galactosamine groups, as shown by paramagnetic relaxation enhancement and NOE NMR constraints.","method":"Solution NMR (PRE, NOE), TEMPO-tagged hexasaccharides, structural modeling","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — NMR structural determination with multiple constraints, direct identification of binding interface","pmids":["25982530"],"is_preprint":false},{"year":2016,"finding":"Crystal structures of CCL5 oligomers reveal polymerization as a double-helical rod. The CCL5 oligomer uses a distinct positively charged KKWVR motif for GAG binding (not the BBXB motif which is partially buried), while CCL3 oligomers use a GAG-binding groove formed by residues from two partially buried BBXB motifs. N-terminal conformational changes in CCL3 alter surface properties and dimer-dimer interfaces to affect GAG binding.","method":"X-ray crystallography, biophysical analysis","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mechanistic interpretation and structural explanation of mutagenesis data","pmids":["27091995"],"is_preprint":false},{"year":2015,"finding":"CCL5 surface presentation on vascular endothelial cells is filamentous and heparan sulfate-dependent; CCL5 mutants restricted in heparin binding, dimerization, or tetramer formation lose filamentous surface organization, appearing granular or undetectable. Filamentous structures persist under flow conditions, suggesting physiological relevance for leukocyte recruitment.","method":"Immunofluorescence, electron microscopy, flow conditions, CCL5 oligomerization/GAG-binding mutants","journal":"Scientific Reports","confidence":"High","confidence_rationale":"Tier 1 — electron microscopy structural characterization with multiple mutagenesis controls and flow conditions","pmids":["25791723"],"is_preprint":false},{"year":2020,"finding":"ASIC1a activation in rheumatoid arthritis synovial fibroblasts mediates Ca2+ influx, which increases [Ca2+]i and activates NFATc3; nuclear NFATc3 directly binds the RANTES/CCL5 promoter and drives CCL5 gene transcription, as shown by ChIP-qPCR and dual-luciferase reporter assay.","method":"Ca2+ imaging, flow cytometry, ChIP-qPCR, dual-luciferase reporter assay, Western blot, immunofluorescence","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 1 — direct ChIP showing NFATc3 binding to CCL5 promoter combined with reporter assay and calcium signaling mechanistic dissection","pmids":["31903118"],"is_preprint":false},{"year":2021,"finding":"CCL5 secreted by pericytes activates CCR5 on glioblastoma cells, enabling DNA-PKcs-mediated DNA damage repair (DDR) upon temozolomide treatment; genetic pericyte depletion or CCR5 antagonist maraviroc inhibits pericyte-promoted DDR and improves chemotherapeutic efficacy.","method":"Pericyte genetic depletion, Co-culture, Western blot for DNA-PKcs activity, GBM xenografts, maraviroc treatment","journal":"Cell Research","confidence":"High","confidence_rationale":"Tier 2 — genetic depletion plus pharmacological inhibition with mechanistic DDR pathway readout, in vivo validation","pmids":["34239070"],"is_preprint":false},{"year":2021,"finding":"CCL5 promotes hippocampal synaptic function and memory by supporting glucose aerobic metabolism, mitochondrial structural integrity, purine synthesis (de novo), and ATP generation; CCL5-knockout mice show impaired hippocampal LTP, reduced synaptic protein expression, and memory deficits reversed by CCL5 re-expression in the hippocampus.","method":"CCL5-KO mice, lentiviral CCL5 re-expression, metabolomics, FDG-PET imaging, seahorse metabolic analysis, electron microscopy of mitochondria, electrophysiology (LTP)","journal":"Molecular Psychiatry","confidence":"High","confidence_rationale":"Tier 1 — KO plus rescue, multiple orthogonal metabolic and electrophysiology methods","pmids":["33931731"],"is_preprint":false},{"year":2021,"finding":"TTP (tristetraprolin) promotes m6A methylation of CCL5 mRNA (and CCL2 mRNA), which accelerates their degradation; TTP overexpression upregulates m6A methylation enzymes (WTAP, METTL14, YTHDF2) and reduces CCL5 mRNA stability, establishing a novel m6A-dependent RNA decay mechanism for CCL5 regulation.","method":"RNA m6A methylation assay, mRNA stability assay, TTP overexpression, m6A methyltransferase expression analysis, in vivo mouse model","journal":"JCI Insight","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic m6A pathway with in vitro and in vivo data, single lab","pmids":["34877932"],"is_preprint":false},{"year":2021,"finding":"CCL5 inhibits influenza A virus replication in alveolar epithelial cells through a PKC-dependent upregulation of the restriction factor SAMHD1; SAMHD1 knockdown abolishes both CCL5-mediated IAV inhibition and CCL5-mediated cell death inhibition.","method":"RT-PCR for restriction factor panel, SAMHD1 siRNA knockdown, viral titer assay, PKC inhibitor","journal":"Frontiers in Cellular and Infection Microbiology","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA knockdown with functional viral replication readout and PKC pharmacological dissection","pmids":["34490131"],"is_preprint":false},{"year":2021,"finding":"EZH2 promotes CCL5 expression in lung cancer cells; EZH2 knockdown reduces CCL5 and macrophage chemotaxis, while EZH2 overexpression increases CCL5; CCL5 knockdown abolishes EZH2-induced macrophage chemotaxis and cancer cell migration/invasion, placing EZH2 upstream of CCL5 in a pro-metastatic pathway.","method":"EZH2 siRNA, CCL5 siRNA, macrophage chemotaxis assay, wound healing, transwell invasion, in vivo xenograft","journal":"Biotechnology and Applied Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis by double knockdown, in vitro and in vivo, single lab","pmids":["31855281"],"is_preprint":false},{"year":2021,"finding":"HIF-1α transcriptionally activates CCL5 expression by binding the CCL5 promoter; inactivation of Cullin-RING ligases (CRLs) by MLN4924 stabilizes HIF-1α levels, increasing CCL5 which drives M2 macrophage infiltration promoting chronic pancreatitis; CCL5 blockade and macrophage depletion both alleviate pancreatic fibrosis.","method":"CRL inactivation (MLN4924), HIF-1α stabilization assay, CCL5 promoter reporter, macrophage depletion, CCL5 blockade, in vivo chronic pancreatitis model","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic HIF-1α→CCL5 axis with promoter data and in vivo models, single lab","pmids":["33723230"],"is_preprint":false},{"year":2023,"finding":"Chordoma cells secrete CCL5 to recruit macrophages via CCR5 and promote their M2 polarization; M2 macrophages reciprocally enhance chordoma proliferation, invasion, and migration; CCL5 knockdown or CCR5 antagonist maraviroc inhibits both M2 polarization and malignant progression in organoids and xenograft models.","method":"Flow cytometry, multiplex IF, CCL5 knockdown, transwell/chemotaxis assay, patient-derived organoids, xenograft mouse model","journal":"Journal for Immunotherapy of Cancer","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and pharmacological CCL5/CCR5 blockade with in vitro and in vivo validation","pmids":["37185233"],"is_preprint":false}],"current_model":"CCL5 (RANTES) is a secreted CC chemokine that functions as a selective chemoattractant for memory T cells, monocytes, and eosinophils by binding its principal receptor CCR5 (a Gi-coupled GPCR), triggering pertussis toxin-insensitive Jak2/Jak3 activation, p38 MAPK signaling, and downstream PI3K/Akt/NF-κB pathways; its activity is critically dependent on N-terminal integrity (Met-RANTES is a full antagonist), higher-order oligomerization (tetramers are the minimal active aggregate for apoptosis induction), and GAG/heparan sulfate binding (which mediates filamentous surface presentation on endothelium and concentrates the gradient for leukocyte recruitment); transcription is controlled by NF-κB, KLF13/RFLAT-1, Fli-1, SP1 (in NK cells via constitutive JNK), and NFATc3 (via Ca2+/ASIC1a), with YB-1 phosphorylation/calcineurin-mediated dephosphorylation providing post-translational regulation of promoter activity, and mRNA stability regulated by TTP-mediated m6A methylation-dependent decay."},"narrative":{"teleology":[{"year":1988,"claim":"Identification of CCL5/RANTES as a novel T-cell-specific gene encoding a small secreted cysteine-rich protein established the founding member of a chemokine subfamily and opened investigation into its immune function.","evidence":"cDNA library screening, Northern blot, sequence analysis of a T-cell-specific transcript","pmids":["2456327"],"confidence":"High","gaps":["No functional activity demonstrated","Receptor unknown","Protein not yet purified"]},{"year":1990,"claim":"Demonstrating that recombinant CCL5 selectively attracts monocytes and memory (UCHL1+) T cells but not naive T cells established its chemotactic specificity and defined it as a bona fide chemokine.","evidence":"Chemotaxis assay with purified and recombinant RANTES, flow cytometric phenotyping of responding cells","pmids":["1699135"],"confidence":"High","gaps":["Receptor identity unknown","Signaling mechanism uncharacterized","In vivo relevance not yet tested"]},{"year":1992,"claim":"Purification of two natural CCL5 forms from platelets (including an O-glycosylated variant) with nanomolar eosinophil chemoattractant potency revealed platelets as a major physiological source and extended the target cell repertoire beyond T cells and monocytes.","evidence":"HPLC purification, electrospray mass spectrometry, eosinophil chemotaxis assay from thrombin-stimulated platelet releasates","pmids":["1380064"],"confidence":"High","gaps":["Receptor identity still unknown","Significance of O-glycosylation for activity not determined"]},{"year":1995,"claim":"The discovery that CCL5 (with MIP-1α and MIP-1β) constitutes the major HIV-suppressive factor from CD8+ T cells fundamentally linked chemokine biology to HIV pathogenesis and foreshadowed the identification of CCR5 as the HIV co-receptor.","evidence":"Protein purification from CD8+ T-cell supernatants, N-terminal sequencing, neutralizing antibody blockade of HIV-1/HIV-2/SIV suppression","pmids":["8525373"],"confidence":"High","gaps":["Mechanism of HIV suppression unknown at this point","Receptor identity not yet confirmed"]},{"year":1996,"claim":"Molecular cloning of CCR5 as the Gi-coupled high-affinity receptor for CCL5, combined with the demonstration that Met-RANTES is a full antagonist and that CCL5 blocks HIV entry through CCR5 in a V3-dependent manner, unified the chemotactic and HIV-suppressive activities under a single receptor system and revealed the critical importance of N-terminal integrity for agonism.","evidence":"Receptor cloning, radioligand binding, calcium flux with pertussis toxin, E. coli-expressed Met-RANTES in calcium/chemotaxis assays, chimeric V3 domain HIV constructs","pmids":["8663314","8699119","8576227","8898753"],"confidence":"High","gaps":["Downstream signaling cascades beyond Gi not characterized","Structural basis of N-terminal activation unknown","Role of oligomerization not addressed"]},{"year":2001,"claim":"Dissection of CCR5 downstream signaling revealed pertussis toxin-insensitive Jak2/Jak3 activation, CCR5 tyrosine phosphorylation, p56lck association with Jak3, and p38 MAPK pathway engagement, distinguishing CCL5/CCR5 signaling from classical Gi-only chemokine cascades; simultaneously, platelet-derived CCL5 was shown to deposit on inflamed endothelium and trigger monocyte arrest under flow.","evidence":"Co-IP and phospho-Western blot in T cells with pertussis toxin and p38 inhibitor controls; parallel-wall flow chamber with Met-RANTES blockade and ex vivo carotid perfusion in apoE−/− mice","pmids":["11278738","11282909"],"confidence":"High","gaps":["No structural information on CCL5-CCR5 complex","Oligomerization requirements for endothelial deposition not tested","Link between Jak signaling and chemotaxis vs. activation not resolved"]},{"year":2002,"claim":"Promoter dissection identified NF-κB as the primary transcriptional activator of CCL5 in epithelial cells upon TNF-α stimulation, with IFN-γ acting post-transcriptionally to stabilize mRNA, establishing stimulus-specific regulatory layers.","evidence":"Promoter deletion/mutagenesis, luciferase reporter, EMSA, and nuclear fractionation in alveolar epithelial cells","pmids":["12388374"],"confidence":"High","gaps":["Chromatin-level regulation not addressed","mRNA stabilization mechanism undefined","Tissue-specific differences in promoter usage unclear"]},{"year":2006,"claim":"Reconstitution experiments with ligand and receptor mutants demonstrated that CCL5-induced T-cell apoptosis requires three cooperating features: GAG binding, higher-order oligomerization (tetramers as the minimal active species), and CCR5 tyrosine-339 phosphorylation, proceeding through the intrinsic apoptotic pathway (cytochrome c/caspase-9/caspase-3).","evidence":"GAG-binding mutant 44AANA47, oligomerization mutant E66S, CCR5-Y339F mutant, caspase activation and cytochrome c release assays","pmids":["16807236"],"confidence":"High","gaps":["Structural basis for why tetramers are the minimal active species unknown","Signaling intermediates between CCR5-pY339 and mitochondrial apoptosis pathway not identified"]},{"year":2007,"claim":"Characterization of the KLF13/NF-κB enhancesome at the CCL5 promoter, with KLF13 itself under translational control, provided a molecular explanation for the characteristic 3–5 day delayed CCL5 expression kinetics in activated T cells, distinct from constitutive NK-cell expression driven by JNK→SP1.","evidence":"Promoter analysis, transcription factor interaction studies, and chromatin modification assays for T cells; MAPK inhibitors, ChIP, EMSA, and SP1-site mutagenesis for NK cells","pmids":["17322928","19124744"],"confidence":"High","gaps":["Translational regulatory mechanism for KLF13 not molecularly defined","Whether enhancesome composition differs across T-cell subsets is unknown"]},{"year":2011,"claim":"Structural determination of CCL5 oligomers as double-helical rod-shaped polymers, with a fully exposed KKWVR GAG-binding motif distinct from the monomer/dimer BBXB site, provided a unified biophysical framework explaining why oligomerization and GAG binding are jointly required for endothelial surface presentation and leukocyte recruitment.","evidence":"NMR, SAXS, hydroxyl radical footprinting, and later X-ray crystallography of CCL5 polymers","pmids":["21827949","27091995","25791723"],"confidence":"High","gaps":["No high-resolution structure of the CCL5–CCR5 signaling complex","Dynamics of oligomer assembly/disassembly on endothelial surfaces not resolved"]},{"year":2014,"claim":"Identification of Fli-1 as a potent CCL5 transcriptional activator via distal Ets promoter sites, and of the Akt-phosphorylated YB-1/calcineurin axis as a post-translational switch controlling CCL5 promoter occupancy during monocyte differentiation, expanded the regulatory network beyond NF-κB and KLF13.","evidence":"ChIP, promoter-reporter/deletion analysis, DNA-binding domain mutagenesis for Fli-1; Co-IP of YB-1–calcineurin, phospho-Ser102-specific analysis, cyclosporine A in vivo for YB-1","pmids":["25098295","24947514"],"confidence":"High","gaps":["Relative contributions of Fli-1 vs. other Ets factors in different immune cell types unknown","Whether YB-1 phosphorylation integrates with the KLF13 enhancesome is untested"]},{"year":2021,"claim":"Multiple studies revealed expanded functional roles for CCL5: support of hippocampal synaptic plasticity via mitochondrial metabolism and purine synthesis (demonstrated by KO and rescue); TTP-mediated m6A-dependent mRNA decay as a post-transcriptional off-switch; and tumor microenvironment remodeling through CCR5-dependent DNA damage repair in glioblastoma and macrophage M2 polarization in multiple cancers.","evidence":"CCL5-KO mice with lentiviral rescue, metabolomics, FDG-PET, and LTP electrophysiology; TTP overexpression with m6A methylation and mRNA stability assays; pericyte depletion/maraviroc in GBM xenografts; CCL5/CCR5 blockade in chordoma organoids and xenografts","pmids":["33931731","34877932","34239070","37185233"],"confidence":"High","gaps":["Receptor and signaling pathway mediating CCL5's metabolic effects in neurons not identified","Whether TTP-m6A mechanism operates in all CCL5-expressing cell types is unknown","Relative contribution of CCL5 vs. other CCR5 ligands in tumor immune evasion unclear"]},{"year":null,"claim":"A high-resolution structure of the CCL5–CCR5 signaling complex, the mechanism linking CCR5 Y339 phosphorylation to divergent outcomes (chemotaxis vs. apoptosis), and the identity of the receptor mediating CCL5's neuronal metabolic effects remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No experimental CCL5–CCR5 co-structure","Signaling branch point between chemotaxis, survival, and apoptosis undefined","Neuronal CCL5 receptor and metabolic signaling pathway uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[1,2,4,5,7,19]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[12,17,18]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,2,4,12,18,37]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,2,4,7,12,13,19,20,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,8,13,21,24,28,30]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[19]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[2,12,17,18]}],"complexes":[],"partners":["CCR5","CCR1","PF4","KLF13","YB1","NFATC3","FLI1","SP1"],"other_free_text":[]},"mechanistic_narrative":"CCL5 (RANTES) is a secreted CC-family chemokine that serves as a principal chemoattractant for monocytes, memory T lymphocytes, and eosinophils, and plays broader roles in angiogenesis, neuronal synaptic function, and tumor microenvironment remodeling [PMID:1699135, PMID:1380064, PMID:22752444, PMID:33931731]. CCL5 signals primarily through the Gi-coupled receptor CCR5, activating Jak2/Jak3, p38 MAPK, PI3K/Akt, and NF-κB cascades; its agonist activity is critically dependent on N-terminal integrity, as Met-RANTES acts as a full antagonist [PMID:8663314, PMID:11278738, PMID:8576227]. Higher-order oligomerization into double-helical rod polymers and glycosaminoglycan binding via a surface-exposed KKWVR motif cooperate to enable filamentous presentation on activated endothelium, which is required for shear-resistant leukocyte arrest and apoptosis induction through CCR5 [PMID:27091995, PMID:25791723, PMID:16807236]. Transcription is controlled by NF-κB, KLF13/RFLAT-1 (governing delayed T-cell expression), Fli-1, SP1 (constitutive in NK cells via JNK), NFATc3, and HIF-1α, while post-transcriptionally, TTP promotes m6A-dependent mRNA decay and YB-1 phosphorylation/calcineurin-mediated dephosphorylation modulates promoter occupancy [PMID:12388374, PMID:11138780, PMID:25098295, PMID:19124744, PMID:31903118, PMID:34877932, PMID:24947514]."},"prefetch_data":{"uniprot":{"accession":"P13501","full_name":"C-C motif chemokine 5","aliases":["EoCP","Eosinophil chemotactic cytokine","SIS-delta","Small-inducible cytokine A5","T cell-specific protein P228","TCP228","T-cell-specific protein RANTES"],"length_aa":91,"mass_kda":10.0,"function":"Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) (PubMed:1380064, PubMed:15923218, PubMed:16791620, PubMed:8525373, PubMed:9516414). May also be an agonist of the G protein-coupled receptor GPR75, stimulating inositol trisphosphate production and calcium mobilization through its activation. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells (PubMed:23979485)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P13501/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL5","classification":"Not Classified","n_dependent_lines":16,"n_total_lines":1208,"dependency_fraction":0.013245033112582781},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL5","total_profiled":1310},"omim":[{"mim_id":"613766","title":"SECRETORY CARRIER MEMBRANE PROTEIN 5; SCAMP5","url":"https://www.omim.org/entry/613766"},{"mim_id":"613665","title":"ATYPICAL CHEMOKINE RECEPTOR 1; ACKR1","url":"https://www.omim.org/entry/613665"},{"mim_id":"612672","title":"RAS-ASSOCIATED PROTEIN RAB10; RAB10","url":"https://www.omim.org/entry/612672"},{"mim_id":"611387","title":"CXC CHEMOKINE LIGAND 17; CXCL17","url":"https://www.omim.org/entry/611387"},{"mim_id":"610424","title":"HEPATITIS B VIRUS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/610424"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":114.7},{"tissue":"lymphoid tissue","ntpm":126.6}],"url":"https://www.proteinatlas.org/search/CCL5"},"hgnc":{"alias_symbol":["RANTES","SISd","TCP228","MGC17164"],"prev_symbol":["D17S136E","SCYA5"]},"alphafold":{"accession":"P13501","domains":[{"cath_id":"2.40.50.40","chopping":"32-91","consensus_level":"medium","plddt":97.2378,"start":32,"end":91}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P13501","model_url":"https://alphafold.ebi.ac.uk/files/AF-P13501-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P13501-F1-predicted_aligned_error_v6.png","plddt_mean":88.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL5","jax_strain_url":"https://www.jax.org/strain/search?query=CCL5"},"sequence":{"accession":"P13501","fasta_url":"https://rest.uniprot.org/uniprotkb/P13501.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P13501/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P13501"}},"corpus_meta":[{"pmid":"18439751","id":"PMC_18439751","title":"The inflammatory chemokines CCL2 and CCL5 in breast cancer.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/18439751","citation_count":481,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11282909","id":"PMC_11282909","title":"RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium.","date":"2001","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/11282909","citation_count":463,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24523569","id":"PMC_24523569","title":"The inflammatory chemokine CCL5 and cancer progression.","date":"2014","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24523569","citation_count":354,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32630699","id":"PMC_32630699","title":"The CCL5/CCR5 Axis in Cancer Progression.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32630699","citation_count":308,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34514075","id":"PMC_34514075","title":"CCL5/CCR5 axis in human diseases and related treatments.","date":"2021","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/34514075","citation_count":265,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7689610","id":"PMC_7689610","title":"Genomic organization and transcriptional regulation of the RANTES chemokine gene.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7689610","citation_count":258,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20978355","id":"PMC_20978355","title":"Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice.","date":"2010","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20978355","citation_count":228,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11424873","id":"PMC_11424873","title":"MCP-1 and RANTES are mediators of acute and chronic inflammation.","date":"2001","source":"Allergy and asthma proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/11424873","citation_count":219,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25901081","id":"PMC_25901081","title":"CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25901081","citation_count":184,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19893003","id":"PMC_19893003","title":"CCL5 promotes macrophage recruitment and survival in human adipose tissue.","date":"2009","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19893003","citation_count":181,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34239070","id":"PMC_34239070","title":"Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling.","date":"2021","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34239070","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19779041","id":"PMC_19779041","title":"Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19779041","citation_count":122,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17322928","id":"PMC_17322928","title":"Mechanisms of disease: regulation of RANTES (CCL5) in renal disease.","date":"2007","source":"Nature clinical practice. Nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/17322928","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16873271","id":"PMC_16873271","title":"Role of CCL5 (RANTES) in viral lung disease.","date":"2006","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/16873271","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7537968","id":"PMC_7537968","title":"Glucocorticoid inhibition of RANTES expression in human lung epithelial cells.","date":"1995","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7537968","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25256399","id":"PMC_25256399","title":"The potential to target CCL5/CCR5 in breast cancer.","date":"2014","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/25256399","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19665464","id":"PMC_19665464","title":"Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice.","date":"2009","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19665464","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11278738","id":"PMC_11278738","title":"Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278738","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22506069","id":"PMC_22506069","title":"CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22506069","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24252748","id":"PMC_24252748","title":"TLR4, rather than TLR2, regulates wound healing through TGF-β and CCL5 expression.","date":"2013","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/24252748","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22752444","id":"PMC_22752444","title":"RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans.","date":"2012","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22752444","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8742071","id":"PMC_8742071","title":"RANTES chemokine expression in diseased and normal human tissues.","date":"1996","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/8742071","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28011329","id":"PMC_28011329","title":"Functional role of CCL5/RANTES for HCC progression during chronic liver disease.","date":"2016","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/28011329","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11849411","id":"PMC_11849411","title":"Early application of Met-RANTES ameliorates chronic allograft nephropathy.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/11849411","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11138780","id":"PMC_11138780","title":"Transcriptional regulation of RANTES expression in T lymphocytes.","date":"2000","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/11138780","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21827949","id":"PMC_21827949","title":"Oligomeric structure of the chemokine CCL5/RANTES from NMR, MS, and SAXS data.","date":"2011","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/21827949","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14687724","id":"PMC_14687724","title":"A dual role for tumor-derived chemokine RANTES (CCL5).","date":"2003","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/14687724","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22103502","id":"PMC_22103502","title":"Angiogenic properties of the chemokine RANTES/CCL5.","date":"2011","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/22103502","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11000125","id":"PMC_11000125","title":"Inducible lung-specific expression of RANTES: preferential recruitment of neutrophils.","date":"2000","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11000125","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27091995","id":"PMC_27091995","title":"Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27091995","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31747383","id":"PMC_31747383","title":"Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme.","date":"2019","source":"Radiology and oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31747383","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16807236","id":"PMC_16807236","title":"CCL5-CCR5-mediated apoptosis in T cells: Requirement for glycosaminoglycan binding and CCL5 aggregation.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16807236","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26377571","id":"PMC_26377571","title":"RANTES and SDF-1 Are Keys in Cell-based Therapy of TMJ Osteoarthritis.","date":"2015","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/26377571","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26420723","id":"PMC_26420723","title":"Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer.","date":"2015","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26420723","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21593768","id":"PMC_21593768","title":"A GPR40 agonist GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation.","date":"2011","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21593768","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12388374","id":"PMC_12388374","title":"Regulation of RANTES promoter activation in alveolar epithelial cells after cytokine stimulation.","date":"2002","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12388374","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31903118","id":"PMC_31903118","title":"ASIC1a induces synovial inflammation via the Ca2+/NFATc3/ RANTES pathway.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31903118","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19682436","id":"PMC_19682436","title":"Involvement of matrix metalloproteinase-3 in CCL5/CCR5 pathway of chondrosarcomas metastasis.","date":"2009","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19682436","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11970912","id":"PMC_11970912","title":"Interferon-gamma enhances rhinovirus-induced RANTES secretion by airway epithelial cells.","date":"2002","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11970912","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18247131","id":"PMC_18247131","title":"The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.","date":"2007","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18247131","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12112372","id":"PMC_12112372","title":"RANTES stimulates inflammatory cascades and receptor modulation in murine astrocytes.","date":"2002","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/12112372","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9357137","id":"PMC_9357137","title":"Switching gears during T-cell maturation: RANTES and late transcription.","date":"1997","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/9357137","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12603855","id":"PMC_12603855","title":"17beta-estradiol inhibits the production of RANTES in human keratinocytes.","date":"2003","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12603855","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9192918","id":"PMC_9192918","title":"The source and role of RANTES in interstitial lung disease.","date":"1997","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/9192918","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28132854","id":"PMC_28132854","title":"Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28132854","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22943205","id":"PMC_22943205","title":"Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells.","date":"2012","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22943205","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16855620","id":"PMC_16855620","title":"Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes.","date":"2006","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16855620","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20442771","id":"PMC_20442771","title":"Metastasis-inducing S100A4 and RANTES cooperate in promoting tumor progression in mice.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20442771","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37185233","id":"PMC_37185233","title":"Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37185233","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31855281","id":"PMC_31855281","title":"EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer.","date":"2020","source":"Biotechnology and applied biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31855281","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26733422","id":"PMC_26733422","title":"RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis.","date":"2016","source":"Multiple sclerosis (Houndmills, Basingstoke, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26733422","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10495789","id":"PMC_10495789","title":"Regulation of RANTES and ICAM-1 expression in murine mesangial cells.","date":"1997","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/10495789","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12359436","id":"PMC_12359436","title":"Vpr- and Nef-dependent induction of RANTES/CCL5 in microglial cells.","date":"2002","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/12359436","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22750227","id":"PMC_22750227","title":"RANTES, MCP-1 chemokines and factors describing rheumatoid arthritis.","date":"2012","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22750227","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35033156","id":"PMC_35033156","title":"Macrophages-aPKCɩ-CCL5 Feedback Loop Modulates the Progression and Chemoresistance in Cholangiocarcinoma.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35033156","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9552000","id":"PMC_9552000","title":"RANTES-induced T cell activation correlates with CD3 expression.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9552000","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34298673","id":"PMC_34298673","title":"Tumor Extracellular Vesicles Regulate Macrophage-Driven Metastasis through CCL5.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34298673","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25982530","id":"PMC_25982530","title":"Interactions of the Chemokine CCL5/RANTES with Medium-Sized Chondroitin Sulfate Ligands.","date":"2015","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/25982530","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19427874","id":"PMC_19427874","title":"Role of the chemokines CCL3/MIP-1 alpha and CCL5/RANTES in sponge-induced inflammatory angiogenesis in mice.","date":"2009","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/19427874","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25030847","id":"PMC_25030847","title":"CCL5/RANTES is important for inducing osteogenesis of human mesenchymal stem cells and is regulated by dexamethasone.","date":"2014","source":"Bioscience trends","url":"https://pubmed.ncbi.nlm.nih.gov/25030847","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19124744","id":"PMC_19124744","title":"JNK MAPK pathway regulates constitutive transcription of CCL5 by human NK cells through SP1.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19124744","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25098295","id":"PMC_25098295","title":"The Fli-1 transcription factor regulates the expression of CCL5/RANTES.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25098295","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21719482","id":"PMC_21719482","title":"IκBα glutathionylation and reduced histone H3 phosphorylation inhibit eotaxin and RANTES.","date":"2011","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/21719482","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24965094","id":"PMC_24965094","title":"Elucidating a key anti-HIV-1 and cancer-associated axis: the structure of CCL5 (Rantes) in complex with CCR5.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24965094","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24947514","id":"PMC_24947514","title":"Calcineurin-mediated YB-1 dephosphorylation regulates CCL5 expression during monocyte differentiation.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24947514","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22962966","id":"PMC_22962966","title":"Induction of IL-6 and CCL5 (RANTES) in human respiratory epithelial (A549) cells by clinical isolates of respiratory syncytial virus is strain specific.","date":"2012","source":"Virology journal","url":"https://pubmed.ncbi.nlm.nih.gov/22962966","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16455992","id":"PMC_16455992","title":"CCL5 modulates pneumococcal immunity and carriage.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16455992","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15975820","id":"PMC_15975820","title":"IL-17 reduces TNF-induced Rantes and VCAM-1 expression.","date":"2005","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/15975820","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21942811","id":"PMC_21942811","title":"Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples.","date":"2011","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21942811","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33931731","id":"PMC_33931731","title":"CCL5 promotion of bioenergy metabolism is crucial for hippocampal synapse complex and memory formation.","date":"2021","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/33931731","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10433951","id":"PMC_10433951","title":"Effects of reactive oxygen and nitrogen metabolites on RANTES- and IL-5-induced eosinophil chemotactic activity in vitro.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10433951","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27863423","id":"PMC_27863423","title":"Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27863423","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33723230","id":"PMC_33723230","title":"Neddylation pathway alleviates chronic pancreatitis by reducing HIF1α-CCL5-dependent macrophage infiltration.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33723230","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15589034","id":"PMC_15589034","title":"The expression of RANTES and chemokine receptors in the brains of scrapie-infected mice.","date":"2005","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/15589034","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16547971","id":"PMC_16547971","title":"CCL5 evokes calcium signals in microglia through a kinase-, phosphoinositide-, and nucleotide-dependent mechanism.","date":"2006","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/16547971","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25280942","id":"PMC_25280942","title":"IL-32θ downregulates CCL5 expression through its interaction with PKCδ and STAT3.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25280942","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32973762","id":"PMC_32973762","title":"Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma Regression.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32973762","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15377675","id":"PMC_15377675","title":"Recombinant guinea pig CCL5 (RANTES) differentially modulates cytokine production in alveolar and peritoneal macrophages.","date":"2004","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/15377675","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34877932","id":"PMC_34877932","title":"TTP protects against acute liver failure by regulating CCL2 and CCL5 through m6A RNA methylation.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/34877932","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33664576","id":"PMC_33664576","title":"Research Trends and Regulation of CCL5 in Prostate Cancer.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33664576","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33781821","id":"PMC_33781821","title":"Role of myeloid-derived chemokine CCL5/RANTES at an early stage of atherosclerosis.","date":"2021","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/33781821","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39535362","id":"PMC_39535362","title":"Integrin β8 Facilitates Macrophage Infiltration and Polarization by Regulating CCL5 to Promote LUAD Progression.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39535362","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25791723","id":"PMC_25791723","title":"Oligomerized, filamentous surface presentation of RANTES/CCL5 on vascular endothelial cells.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/25791723","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16756635","id":"PMC_16756635","title":"Messenger RNA expression of RANTES in the urinary sediment of patients with lupus nephritis.","date":"2006","source":"Nephrology (Carlton, Vic.)","url":"https://pubmed.ncbi.nlm.nih.gov/16756635","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34716323","id":"PMC_34716323","title":"CircETFA upregulates CCL5 by sponging miR-612 and recruiting EIF4A3 to promote hepatocellular carcinoma.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34716323","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9759898","id":"PMC_9759898","title":"A RANTES-antibody fusion protein retains antigen specificity and chemokine function.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9759898","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34490131","id":"PMC_34490131","title":"The Chemokine CCL5 Inhibits the Replication of Influenza A Virus Through SAMHD1 Modulation.","date":"2021","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/34490131","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18700040","id":"PMC_18700040","title":"CCL5 regulation of mucosal chlamydial immunity and infection.","date":"2008","source":"BMC microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/18700040","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20452453","id":"PMC_20452453","title":"Role of CCL3/MIP-1alpha and CCL5/RANTES during acute Trypanosoma cruzi infection in rats.","date":"2010","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/20452453","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22292067","id":"PMC_22292067","title":"Regulation of CCL5 expression in smooth muscle cells following arterial injury.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22292067","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17978871","id":"PMC_17978871","title":"Tumor-derived CCL5 does not contribute to breast cancer progression.","date":"2007","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/17978871","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14579276","id":"PMC_14579276","title":"Intrapulmonary targeting of RANTES/CCL5-responsive cells prevents chronic fungal asthma.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14579276","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37769321","id":"PMC_37769321","title":"The intricate role of CCL5/CCR5 axis in Alzheimer disease.","date":"2023","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37769321","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21671175","id":"PMC_21671175","title":"Role of RANTES and its receptor in gastric cancer metastasis.","date":"2011","source":"Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban","url":"https://pubmed.ncbi.nlm.nih.gov/21671175","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12819056","id":"PMC_12819056","title":"Helicobacter pylori induces RANTES through activation of NF-kappa B.","date":"2003","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12819056","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25623966","id":"PMC_25623966","title":"Pharmacological induction of CCL5 in vivo prevents gp120-mediated neuronal injury.","date":"2015","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25623966","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15817160","id":"PMC_15817160","title":"Macaque trophoblast migration is regulated by RANTES.","date":"2005","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15817160","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31557402","id":"PMC_31557402","title":"ALPK1 regulates streptozotocin-induced nephropathy through CCL2 and CCL5 expressions.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31557402","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38719543","id":"PMC_38719543","title":"CCR5 and CCL5 in metastatic colorectal cancer.","date":"2024","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38719543","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33472520","id":"PMC_33472520","title":"Impact of Plasma IP-10/CXCL10 and RANTES/CCL5 Levels on Neurocognitive Function in HIV Treatment-Naive Patients.","date":"2021","source":"AIDS research and human retroviruses","url":"https://pubmed.ncbi.nlm.nih.gov/33472520","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8525373","id":"PMC_8525373","title":"Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8525373","citation_count":2550,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1699135","id":"PMC_1699135","title":"Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES.","date":"1990","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1699135","citation_count":1317,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1380064","id":"PMC_1380064","title":"Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils.","date":"1992","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1380064","citation_count":638,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9826729","id":"PMC_9826729","title":"Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9826729","citation_count":569,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9359702","id":"PMC_9359702","title":"In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.","date":"1997","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9359702","citation_count":530,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2456327","id":"PMC_2456327","title":"A human T cell-specific molecule is a member of a new gene family.","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2456327","citation_count":461,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8898753","id":"PMC_8898753","title":"The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection.","date":"1996","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8898753","citation_count":450,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8642344","id":"PMC_8642344","title":"Cloning, expression, and characterization of the human eosinophil eotaxin receptor.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8642344","citation_count":441,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18678243","id":"PMC_18678243","title":"Peripheral cytokines profile in Parkinson's disease.","date":"2008","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18678243","citation_count":425,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8663314","id":"PMC_8663314","title":"Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8663314","citation_count":393,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23152559","id":"PMC_23152559","title":"Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23152559","citation_count":354,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11350939","id":"PMC_11350939","title":"Chemokine receptor homo- or heterodimerization activates distinct signaling pathways.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11350939","citation_count":351,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8576227","id":"PMC_8576227","title":"Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8576227","citation_count":343,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15890969","id":"PMC_15890969","title":"Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium.","date":"2005","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15890969","citation_count":336,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15280531","id":"PMC_15280531","title":"NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy.","date":"2004","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/15280531","citation_count":323,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15459010","id":"PMC_15459010","title":"Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15459010","citation_count":295,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10200305","id":"PMC_10200305","title":"Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10200305","citation_count":279,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11500196","id":"PMC_11500196","title":"Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients.","date":"2001","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/11500196","citation_count":264,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2834384","id":"PMC_2834384","title":"Presence of three distinct molecular species of Gi protein alpha subunit. Structure of rat cDNAs and human genomic DNAs.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2834384","citation_count":256,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8699119","id":"PMC_8699119","title":"Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES.","date":"1996","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/8699119","citation_count":245,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19156204","id":"PMC_19156204","title":"IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19156204","citation_count":244,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12753088","id":"PMC_12753088","title":"MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis.","date":"2003","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12753088","citation_count":242,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21486440","id":"PMC_21486440","title":"Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition.","date":"2011","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21486440","citation_count":236,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22637726","id":"PMC_22637726","title":"CCR5 antagonist blocks metastasis of basal breast cancer cells.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22637726","citation_count":236,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23898208","id":"PMC_23898208","title":"Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23898208","citation_count":235,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50842,"output_tokens":9860,"usd":0.150213},"stage2":{"model":"claude-opus-4-6","input_tokens":13929,"output_tokens":5576,"usd":0.313567},"total_usd":0.895202,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":65455,"output_tokens":10823,"usd":0.179355},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":15184,"output_tokens":3685,"usd":0.252067}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL5/RANTES secreted by thrombin-stimulated platelets is immobilized on the surface of inflamed microvascular or aortic endothelium (requiring endothelial activation by IL-1β) and triggers shear-resistant monocyte arrest under flow conditions, as blocked by Met-RANTES receptor antagonist or anti-RANTES antibody.\",\n      \"method\": \"Parallel-wall flow chamber with video microscopy, ELISA/immunofluorescence binding assay, ex vivo murine carotid artery perfusion, immunohistochemistry in ApoE-deficient mice\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (flow chamber, antibody blockade, in vivo model), replicated with pharmacological and genetic approaches\",\n      \"pmids\": [\"11282909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL5 (RANTES) activates Jak2 and Jak3 in CCR5-expressing T cells, leading to Stat1/Stat3 phosphorylation and p38 MAP kinase pathway activation (including MAPKAP kinase-2). This Jak phosphorylation is insensitive to pertussis toxin, indicating it is not coupled directly to Gαi. CCL5 also induces tyrosine phosphorylation of Src kinase p56lck, which associates with Jak3.\",\n      \"method\": \"Western blotting for phosphorylated Jak2, Jak3, p56lck, p38 MAPK and MAPKAP kinase-2 in PM1 T cells; pertussis toxin inhibition; pharmacological kinase inhibitors\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple signaling components assayed with orthogonal inhibitors in a single study\",\n      \"pmids\": [\"11278738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL5-induced apoptosis in CCR5-expressing T cells requires: (1) cell-surface glycosaminoglycan (GAG) binding (non-GAG-binding mutant [44AANA47]-CCL5 fails to induce apoptosis; exogenous heparin/chondroitin sulfate or GAG digestion protects cells); (2) CCL5 oligomerization to at least tetramers (non-aggregating E66S mutant forming dimers fails, whereas E26A tetramer-forming mutant is sufficient); (3) CCR5 tyrosine 339 (CCR5Y339F mutant abolishes apoptosis). The pathway involves cytochrome c release and caspase-9/caspase-3 activation.\",\n      \"method\": \"CCR5 mutant receptor expression, GAG modification assays (exogenous GAG addition, enzymatic digestion), CCL5 oligomerization mutants, caspase activity assays, cytochrome c release, PARP cleavage\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with multiple mutants (receptor and ligand) plus biochemical pathway dissection in single study\",\n      \"pmids\": [\"16807236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCL5 forms rod-shaped, double-helical oligomers (polymerization process); the KKWVR motif (not the partially buried BBXB motif) mediates GAG binding in CCL5 oligomers. Mutations at E66 and E26 explain the disaggregating effect of these residues. GAG binding promotes oligomer formation.\",\n      \"method\": \"Crystal structure of CCL5 oligomers (X-ray crystallography), biophysical analyses including GAG-bound complex structures\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis and biophysical validation\",\n      \"pmids\": [\"27091995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The solution structure of CCL5 oligomers larger than the canonical dimer was determined; CCL5 oligomerization is essential for T cell activation, apoptosis, and HIV entry. Residues E66 and E26 are at oligomer interfaces (explaining disaggregating mutations). GAG binding via the surface promotes oligomer formation and facilitates in vivo cell migration.\",\n      \"method\": \"NMR residual dipolar couplings, SAXS, hydroxyl radical footprinting, NMR cross-saturation experiments\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multi-method structural determination (NMR + SAXS + footprinting) in single study\",\n      \"pmids\": [\"21827949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In the CCL5 dimer, GAG (chondroitin sulfate) contacts both the BBXB motif in the 40s loop and residues in the N loop (similar to receptor N-terminus interactions). Binding orientation is highly dependent on sulfation pattern of N-acetylgalactosamine groups.\",\n      \"method\": \"Solution NMR with TEMPO-tagged hexasaccharides, paramagnetic relaxation enhancement, intermolecular NOE constraints\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structural study with paramagnetic probes defining binding contacts\",\n      \"pmids\": [\"25982530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RANTES/CCL5 binds to the surface of human endothelial cells in a regular filamentous pattern dependent on heparan sulfate. CCL5 mutants restricted in heparin binding (non-filamentous/granular pattern) or in forming dimers/tetramers are not detectable or appear non-filamentous, correlating with their lack of in vivo leukocyte recruitment activity.\",\n      \"method\": \"Immunofluorescence microscopy, electron microscopy, flow chamber exposure, CCL5 oligomerization/GAG-binding mutants on endothelial cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with functional mutant correlation, single lab\",\n      \"pmids\": [\"25791723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The CCL5/RANTES gene spans ~7.1 kb with three exons and two introns; the ~1 kb 5′ upstream promoter contains consensus elements for T cell/hematopoietic, myeloid, muscle, and ubiquitous DNA-binding factors. Promoter-luciferase assays show high activity in mature T cell (Hut78) and erythroleukemic (HEL) lines but not in early T cell or pre-erythroid lines, with deletion analysis indicating cell-type-specific transcriptional mechanisms.\",\n      \"method\": \"Genomic cloning, promoter-luciferase reporter assays, deletion analysis in multiple cell lines\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional promoter dissection with deletion analysis across multiple cell types\",\n      \"pmids\": [\"7689610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"RANTES factor of late activated T lymphocytes (RFLAT-1), a Krüppel-like transcription factor (KLF13), drives late (3–5 day) CCL5 expression in T cells. Unlike RANTES, RFLAT-1 expression is regulated translationally rather than transcriptionally after T cell activation.\",\n      \"method\": \"Transcription factor identification, promoter assays, assessment of transcriptional vs. translational regulation\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — identification of transcription factor with functional promoter assays, single lab\",\n      \"pmids\": [\"11138780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CCL5 transcription in T lymphocytes 3–5 days after activation requires an enhancesome complex including KLF13, NF-κB subunits p50 and p65, and scaffolding proteins; this complex recruits chromatin-modifying enzymes for acetylation, methylation, and phosphorylation. KLF13 is itself translationally regulated.\",\n      \"method\": \"Review synthesizing chromatin immunoprecipitation, co-immunoprecipitation, and transcriptional reporter studies from primary literature\",\n      \"journal\": \"Nature clinical practice. Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic synthesis based on co-IP and ChIP data described in primary studies\",\n      \"pmids\": [\"17322928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CCL5 transcription in alveolar epithelial cells is primarily controlled by NF-κB, with additional roles for NF-IL6, CRE, and ISRE elements. TNF-α induces IRF-3 nuclear translocation but IRF-3 does not bind the RANTES ISRE under TNF stimulation (unlike viral infection), demonstrating stimulus-specific enhancer control. IFN-γ stabilizes RANTES mRNA but does not activate transcription.\",\n      \"method\": \"Promoter deletion/mutagenesis with luciferase reporters, EMSA for NF-κB and IRF-3 binding, mRNA stability assays in A549 cells\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic promoter mutagenesis with multiple cis-element analysis and EMSA\",\n      \"pmids\": [\"12388374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In NK cells, constitutive CCL5 expression is controlled by the JNK/MAPK pathway through binding of transcription factor SP1 to a region −75 to −56 upstream of the transcription initiation site. ERK and p38 pathways do not contribute. SP1 expression itself is maintained by constitutive JNK activation in peripheral blood NK cells.\",\n      \"method\": \"Specific MAPK pathway inhibitors, promoter-reporter assays, EMSA, chromatin immunoprecipitation (ChIP), site-directed mutagenesis of SP1 binding site\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods (inhibitors + ChIP + mutagenesis) in single study\",\n      \"pmids\": [\"19124744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The Ets family transcription factor Fli-1 directly binds Ets binding sites in the distal region of the CCL5 promoter and drives CCL5 transcription in a dose-dependent manner. Fli-1 knockdown reduces CCL5 protein in endothelial cells. Ets1 acts as a dominant-negative for Fli-1 at shared binding sites. Mutation of the Fli-1 DNA-binding domain significantly reduces transactivation.\",\n      \"method\": \"ChIP of endogenous CCL5 promoter, siRNA knockdown, transient transfection reporter assays, systematic promoter deletion, dominant-negative mutant\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP + mutagenesis + siRNA knockdown with multiple controls\",\n      \"pmids\": [\"25098295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"YB-1 phosphorylated at Ser-102 (via Akt signaling) binds to and transactivates the CCL5 promoter during monocyte/macrophage differentiation. Calcineurin directly interacts with YB-1 (shown by Co-IP) and dephosphorylates Ser-102, preventing YB-1 from binding the CCL5 promoter and thereby down-regulating CCL5 expression at later differentiation stages.\",\n      \"method\": \"Co-immunoprecipitation (YB-1/calcineurin interaction), ChIP (YB-1 binding to CCL5 promoter), phospho-specific immunoblotting, cyclosporine A treatment in vivo\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reciprocal Co-IP + ChIP + in vivo pharmacological validation\",\n      \"pmids\": [\"24947514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ASIC1a-mediated Ca²⁺ influx in rheumatoid arthritis synovial fibroblasts activates NFATc3, which translocates to the nucleus and directly binds the RANTES/CCL5 promoter to drive CCL5 transcription and synovial inflammation.\",\n      \"method\": \"Calcium imaging, flow cytometry (Ca²⁺ influx), ChIP-qPCR (NFATc3 binding to CCL5 promoter), dual-luciferase reporter assay, immunofluorescence, Western blot\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP-qPCR + luciferase reporter + Ca²⁺ imaging linking ion channel to CCL5 transcription\",\n      \"pmids\": [\"31903118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IL-32θ interacts with PKCδ and STAT3 (demonstrated by Co-IP and pulldown), leading to STAT3 phosphorylation at Ser727 and subsequent inhibition of STAT3 binding to the CCL5 promoter, thereby reducing CCL5 expression in THP-1 cells.\",\n      \"method\": \"Co-immunoprecipitation, pulldown assay, ELISA (CCL5 protein), promoter binding analysis\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP/pulldown with functional promoter link, single lab\",\n      \"pmids\": [\"25280942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"TNF-α and IL-1β induce RANTES mRNA expression and protein release from lung epithelial cells (A549) in a time- and dose-dependent manner; dexamethasone inhibits TNF-α-induced RANTES mRNA and protein without affecting mRNA half-life and without requiring new protein synthesis, suggesting transcriptional inhibition. TNF-α-induced supernatant promotes eosinophil chemotaxis, which is also inhibited by dexamethasone.\",\n      \"method\": \"mRNA expression (Northern/RT), ELISA protein secretion, mRNA stability assay, eosinophil chemotaxis assay, dexamethasone dose-response in A549 cells\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal assays (mRNA, protein, stability, functional chemotaxis) with mechanistic dissection\",\n      \"pmids\": [\"7537968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"17β-estradiol inhibits TNF-α- or IL-1β-induced RANTES promoter activity and secretion in keratinocytes through estrogen receptor-dependent inhibition of NF-κB transcriptional activity; two NF-κB elements in the RANTES promoter are required. The mechanism involves competition between estrogen receptor and NF-κB p65 for limiting amounts of CREB-binding protein (CBP), without affecting NF-κB DNA binding or IκBα degradation.\",\n      \"method\": \"Promoter-luciferase reporter assays with NF-κB site mutations, ELISA, EMSA (NF-κB DNA binding), phosphorylation assays, CBP overexpression rescue, estrogen receptor transfection\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic promoter mutagenesis, EMSA, and rescue experiments establishing CBP competition mechanism\",\n      \"pmids\": [\"12603855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCL5 interaction with CCR5 in osteosarcoma cells promotes cell migration and αvβ3 integrin upregulation through sequential activation of MEK→ERK→NF-κB signaling; pharmacological inhibitors and dominant-negative mutants of each kinase block CCL5-induced migration and integrin expression. CCL5 increases CCR5 but not CCR1 or CCR3 expression.\",\n      \"method\": \"Migration assay, integrin expression (Western blot/immunofluorescence), specific kinase inhibitors, dominant-negative MEK/ERK/NF-κB mutants, CCR5 siRNA/mAb\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — pathway dissection with inhibitors, dominant-negatives, and siRNA knockdown\",\n      \"pmids\": [\"22506069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL5/CCR5 signaling in chondrosarcoma cells increases MMP-3 expression and migration via the PI3K→Akt→NF-κB pathway; MMP-3 siRNA and inhibitor block CCL5-induced migration, establishing MMP-3 as a downstream effector.\",\n      \"method\": \"Migration assay, MMP-3 expression (Western blot), PI3K/Akt/NF-κB specific inhibitors, MMP-3 siRNA\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway inhibitors with siRNA validation, single lab\",\n      \"pmids\": [\"19682436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RANTES/CCL5-induced pro-angiogenic effects (endothelial cell migration, spreading, neo-vessel formation, VEGF secretion) depend on G-protein-coupled receptors CCR1 and CCR5 as well as heparan sulfate proteoglycans (syndecan-1, syndecan-4, CD44). CCL5 oligomerization (E66A mutant impairs oligomerization) and GAG binding ([44AANA47] mutant) are both required for angiogenic activity. MMP-9 mediates CCL5-induced chemotaxis.\",\n      \"method\": \"In vitro endothelial cell assays (migration, tube formation), rat subcutaneous in vivo angiogenesis model, CCL5 oligomerization and GAG-binding mutants, receptor-blocking antibodies, anti-VEGF receptor antibodies\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro and in vivo approaches with multiple receptor and ligand mutants\",\n      \"pmids\": [\"22752444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Selectin-mediated interactions of tumor cells with platelets and leukocytes activate microvascular endothelial cells to produce CCL5; CCL5-dependent monocyte recruitment during early metastasis promotes tumor cell survival and metastasis establishment, as shown by CCL5 receptor antagonist blockade reducing tumor survival.\",\n      \"method\": \"Microarray of co-cultured endothelial cells, CCL5 receptor antagonist treatment, in vivo metastasis model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — microarray identification + antagonist in vivo validation, single lab\",\n      \"pmids\": [\"19779041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In liver fibrosis, CCL5 (produced mainly by infiltrating hematopoietic cells, as shown by bone marrow transplantation) directly promotes hepatic stellate cell migration, proliferation, and chemokine/collagen secretion via CCL5 receptor signaling; Met-CCL5 antagonist treatment inhibits these effects in vitro and ameliorates/reverses fibrosis in vivo.\",\n      \"method\": \"CCL5 knockout mice, bone marrow transplantation, in vitro stellate cell assays with Met-CCL5, two mouse models of fibrosis (CCl4, MCD diet), in vivo Met-CCL5 treatment\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + BMT identifying cell source + direct in vitro stellate cell mechanism + in vivo rescue\",\n      \"pmids\": [\"20978355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL5 promotes macrophage survival in obese adipose tissue by protecting macrophages from free cholesterol-induced apoptosis via activation of Akt/ERK pathways. CCL5 (but not CCL2) also triggers adhesion and transmigration of blood monocytes through human adipose tissue endothelial cells.\",\n      \"method\": \"Apoptosis assay (Annexin V/PI), Western blot for phospho-Akt/ERK, monocyte transmigration assay\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assays with pathway identification, single lab\",\n      \"pmids\": [\"19893003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Pericyte-secreted CCL5 activates CCR5 on GBM cells to enable DNA-PKcs-mediated DNA damage repair (DDR), inducing temozolomide chemoresistance. Disrupting CCL5-CCR5 signaling with maraviroc (CCR5 antagonist) inhibits pericyte-promoted DDR and improves TMZ efficacy in vivo.\",\n      \"method\": \"Co-culture assay, genetic pericyte depletion in xenografts, DNA-PKcs phosphorylation assay, CCR5 antagonist (maraviroc) treatment, patient-derived xenografts\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic depletion + pharmacological blockade + mechanistic DDR pathway characterization + in vivo validation\",\n      \"pmids\": [\"34239070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL5 promotes hippocampal synapse formation and memory by supporting glycolysis, gluconeogenesis, glutamate and purine metabolism, and mitochondrial integrity/ATP generation. CCL5 knockout mice show impaired LTP, synapse structure loss, and cognitive defects; re-expression in knockout hippocampus restores these functions. CCL5 overexpression in WT mice enhances memory and neuronal connectivity through promotion of de novo purine and glutamate metabolism.\",\n      \"method\": \"CCL5 knockout and rescue (lentiviral re-expression), FDG-PET imaging, metabolomics, Seahorse metabolic analysis, synaptic protein expression, electrophysiology (LTP), behavioral cognitive testing\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO + rescue + multi-omics metabolic characterization with functional readouts\",\n      \"pmids\": [\"33931731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL5 signals through CCR5 in human microglia to elevate intracellular Ca²⁺ via a multi-step cascade requiring Jak activity, inhibitory G protein, PI3K, Bruton's tyrosine kinase (Btk), PLC-mediated IP3-sensitive Ca²⁺ release, and NAD metabolites (cADPR releasing intracellular Ca²⁺; ADPR activating nimodipine-sensitive Ca²⁺ influx).\",\n      \"method\": \"Fura-2 digital Ca²⁺ imaging with pharmacological inhibitors of each signaling component in cultured human microglia\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic pharmacological dissection of Ca²⁺ signaling pathway, single lab\",\n      \"pmids\": [\"16547971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"RANTES/CCL5 stimulates mouse astrocytes to produce chemokines (KC, MCP-1) and TNF-α via G-protein-coupled CCR1 and CCR5 receptors; this is specifically inhibited by pertussis toxin and involves MAP kinase pathway activation. Astrocytes from CCR1-/- or CCR5-/- mice still respond, suggesting redundancy. CCL5 also upregulates ICAM-1 and downregulates CX3CR1 expression on astrocytes.\",\n      \"method\": \"CCR1 and CCR5 knockout mouse astrocyte cultures, pertussis toxin inhibition, chemokine/cytokine mRNA and protein measurement, receptor expression by flow cytometry\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO cells + pharmacological inhibition, single lab\",\n      \"pmids\": [\"12112372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCL5 mRNA induction in vascular smooth muscle cells after arterial injury is mediated by IRF-1 binding to the IRF-1 response element in the CCL5 promoter. p38 MAPK (through MKK3) suppresses CCL5 expression, with the downstream effector MK2 specifically required for p38-mediated CCL5 (but not IP-10) inhibition.\",\n      \"method\": \"Balloon artery injury rat model, mRNA kinetics, promoter binding assay (IRF-1 response element), p38/MKK3/MK2 pathway analysis in rat SMCs\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo injury model + promoter binding + pathway inhibitor analysis, single lab\",\n      \"pmids\": [\"22292067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"H. pylori induces RANTES/CCL5 expression in gastric epithelial cells at the transcriptional level through NF-κB activation via IKK and NIK (kinase-deficient IKK/NIK mutants inhibit RANTES activation); this requires an intact cag pathogenicity island. TNF-α/IL-1 receptor signaling molecules (MEK1, MyD88, IRAK) are not involved.\",\n      \"method\": \"Luciferase reporter assays with RANTES promoter construct, kinase-deficient mutant transfection, co-culture of H. pylori with gastric epithelial cells, isogenic cag PAI mutants\",\n      \"journal\": \"Infection and immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — promoter assay with dominant-negative kinase mutants establishing IKK/NIK pathway specificity\",\n      \"pmids\": [\"12819056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TTP (tristetraprolin) reduces CCL5 (and CCL2) mRNA stability through promotion of N6-methyladenosine (m6A) mRNA methylation; TTP upregulates WTAP, METTL14, and YTHDF2 expression, increasing global m6A methylation and enhancing degradation of CCL5 mRNA, thereby ameliorating acute liver failure.\",\n      \"method\": \"mRNA stability assays, m6A methylation quantification, TTP overexpression/knockdown in vivo (mouse ALF model) and in vitro, measurement of methyltransferase complex components\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mRNA stability + m6A mechanism + in vivo validation, single lab\",\n      \"pmids\": [\"34877932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RANTES-induced second-phase Ca²⁺ signaling (distinct from G-protein-mediated first phase) in T cells correlates directly with CD3 (TCR) expression level; only CD3-high Jurkat cells respond, and prior anti-CD3 stimulation depresses RANTES responses, demonstrating TCR involvement in RANTES-specific signaling pathway.\",\n      \"method\": \"Ca²⁺ flux assay, FACS sorting of CD3high/CD3low Jurkat populations, anti-CD3 pretreatment, CCR5 expression analysis\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell sorting with functional validation, single lab\",\n      \"pmids\": [\"9552000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RANTES/CCL5 expressed by endometrial stromal and vascular endothelial cells guides macrophage trophoblast migration through CCR5; isolated macaque trophoblasts express CCR5, migrate toward RANTES in chemotaxis chambers (blocked by anti-CCR5 antibody), and upregulate β1 integrin expression on RANTES-coated substrate in a pertussis toxin-sensitive (Gi-coupled) manner.\",\n      \"method\": \"Migration chamber assay, RT-PCR and immunocytochemistry (CCR5 expression), anti-CCR5 antibody blockade, pertussis toxin inhibition, β1 integrin expression by immunocytochemistry\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor blocking + pertussis toxin dissection + functional migration assay, single lab\",\n      \"pmids\": [\"15817160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL5 inhibits influenza A virus (IAV) replication in alveolar epithelial cells via upregulation of the restriction factor SAMHD1 through a PKC-dependent pathway; SAMHD1 knockdown abolishes both CCL5-mediated IAV inhibition and CCL5-mediated cell death inhibition.\",\n      \"method\": \"RT-PCR (restriction factor panel), Western blot (SAMHD1 protein), SAMHD1 siRNA knockdown, PKC inhibitor, viral titer measurement\",\n      \"journal\": \"Frontiers in cellular and infection microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown + pharmacological inhibition establishing SAMHD1 as mediator, single lab\",\n      \"pmids\": [\"34490131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCL5 and its receptor CCR1 are both required for osteogenic differentiation of human mesenchymal stem cells; CCL5 expression increases during osteogenesis (regulated by dexamethasone), CCL5 knockdown decreases ALP activity and ALP/BSP/OPN expression, and CCL5 overexpression alone is sufficient to increase ALP expression.\",\n      \"method\": \"CCL5/CCR1 siRNA knockdown, CCL5 overexpression, ALP activity assay, osteogenic marker expression (qPCR/Western blot)\",\n      \"journal\": \"Bioscience trends\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function and gain-of-function with defined phenotypic readouts, single lab\",\n      \"pmids\": [\"25030847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HIF-1α stabilization (through CRL inactivation by MLN4924) increases CCL5 expression by promoting CCL5 gene transactivation; CCL5 mediates M2 macrophage infiltration driving chronic pancreatitis progression. CCL5 blockade and macrophage depletion both reduce pancreatic fibrosis and inflammation.\",\n      \"method\": \"MLN4924 (CRL inhibitor) treatment, HIF-1α stabilization assays, CCL5 promoter transactivation assays, CCL5 blockade in vivo, macrophage depletion, mouse CP model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic HIF-1α→CCL5 link + in vivo blockade validation, single lab\",\n      \"pmids\": [\"33723230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Tumor cell-derived CCL5 stimulates externalization of S100A4 from tumor and stroma cells via microparticle shedding from the plasma membrane. Released S100A4 in turn induces RANTES/CCL5 upregulation in tumor cells and fibronectin in fibroblasts, forming a pro-metastatic feedback loop.\",\n      \"method\": \"Microparticle isolation, S100A4 measurement in plasma, S100A4-deficient mouse model, wound-healing assay, in vivo metastasis quantification\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO mouse + in vitro mechanistic assays + in vivo validation, single lab\",\n      \"pmids\": [\"20442771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The cannabinoid THC inhibits macrophage chemotaxis to CCL5/RANTES specifically through the CB2 receptor: CB2-selective ligand O-2137 robustly inhibits chemotaxis; CB2-selective antagonist SR144528 reverses THC inhibition; THC has minimal effect on CB2 knockout macrophages; CB1-selective antagonist does not reverse THC inhibition.\",\n      \"method\": \"Macrophage chemotaxis assay, CB1/CB2 selective agonists/antagonists, CB2 knockout mice\",\n      \"journal\": \"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor selectivity established with genetic KO + pharmacological tools, single lab\",\n      \"pmids\": [\"18247131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A computational model of the CCL5:CCR5 complex structure was derived using free energy calculations and molecular dynamics simulations; the structure reveals polar and non-polar interactions contributing to CCL5:CCR5 binding and clarifies that both CCL5 and HIV-1 gp120 V3 loop primarily interact with the same CCR5 residues.\",\n      \"method\": \"Computational free energy calculations, molecular dynamics simulations, validated against available experimental binding/signaling data\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational prediction validated against existing experimental data but no new experimental confirmation\",\n      \"pmids\": [\"24965094\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL5 (RANTES) is a secreted CC chemokine that signals primarily through CCR5 (and CCR1/CCR3) to activate multiple intracellular cascades—including Jak2/Jak3, Stat1/Stat3, p38 MAPK, PI3K/Akt, ERK, and PLC/Ca²⁺—and exerts its full in vivo functions (leukocyte arrest, migration, T cell activation, apoptosis) only as higher-order oligomers that bind glycosaminoglycans on cell surfaces and extracellular matrix through a distinct KKWVR motif; its transcription is cell-type-specifically regulated by NF-κB, KLF13/RFLAT-1, Fli-1, IRF-1, and SP1 (in NK cells via the JNK pathway), and is post-transcriptionally modulated via YB-1 phosphorylation/calcineurin dephosphorylation and m6A-dependent mRNA stability, while its biological roles span monocyte/leukocyte recruitment, hepatic stellate cell activation driving fibrosis, DNA damage repair in cancer cells (via CCR5→DNA-PKcs), hippocampal synaptic function through metabolic support, and restriction of viral replication through SAMHD1 upregulation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"CCL5 (RANTES) was identified as a novel T cell-specific secreted molecule belonging to a new gene family of small proteins characterized by conserved cysteine residues; the gene product is predicted to be ~8 kDa after signal peptide cleavage with 4 cysteines and no N-linked glycosylation sites.\",\n      \"method\": \"cDNA library screening, sequence analysis, Northern blot\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning and characterization paper, foundational discovery, highly cited\",\n      \"pmids\": [\"2456327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"CCL5/RANTES protein selectively attracts human blood monocytes and CD4+/UCHL1+ memory T lymphocytes but not naive T cells, demonstrating chemokine activity for specific leukocyte subsets.\",\n      \"method\": \"Chemotaxis assay with purified/recombinant RANTES, flow cytometry cell phenotyping\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro functional assay, foundational paper with >1300 citations\",\n      \"pmids\": [\"1699135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CCL5/RANTES released by thrombin-stimulated platelets is a potent eosinophil chemoattractant; purification revealed two natural forms: a full-length form (EoCP-2, ~7,863 Da, with methionine oxidation) and an O-glycosylated form (EoCP-1, ~8,355 Da), both with ED50 ~2 nM for eosinophil chemotaxis.\",\n      \"method\": \"HPLC purification, NH2-terminal sequencing, electrospray mass spectrometry, eosinophil chemotaxis assay\",\n      \"journal\": \"Journal of Experimental Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purification to homogeneity, mass spectrometry, direct functional assay, replicated with recombinant material\",\n      \"pmids\": [\"1380064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The RANTES/CCL5 gene spans ~7.1 kb, is composed of 3 exons (133, 112, and 1075 bases) and 2 introns, with conserved intron/exon boundaries relative to other CC chemokines. The ~1 kb promoter contains consensus elements for T cell/hematopoietic, myeloid, and ubiquitous transcription factors; promoter activity is cell-type specific (high in mature T cells and erythroleukemic cells, absent in early T cell lines).\",\n      \"method\": \"Genomic cloning, promoter-luciferase reporter assays, deletion analysis\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct functional promoter mapping with multiple deletion constructs in multiple cell lines\",\n      \"pmids\": [\"7689610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CCL5/RANTES (together with MIP-1α and MIP-1β) was identified as a major HIV-suppressive factor produced by CD8+ T cells; recombinant CCL5 dose-dependently inhibited HIV-1, HIV-2, and SIV, and combination neutralizing antibodies against all three chemokines abrogated CD8+ T cell HIV-suppressive activity.\",\n      \"method\": \"Protein purification from CD8+ T cell supernatants, N-terminal sequencing, neutralizing antibody blockade, HIV replication assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purification, sequencing, and functional neutralization, foundational paper with >2500 citations\",\n      \"pmids\": [\"8525373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Retention of the initiating methionine (Met-RANTES) completely abolishes CCL5 agonist activity in calcium mobilization and chemotaxis assays while producing a potent selective antagonist of both RANTES and MIP-1α through competition for their shared receptor CC-CKR-1, demonstrating that the integrity of the amino terminus is critical for receptor activation.\",\n      \"method\": \"Recombinant protein expression in E. coli, calcium flux assay, chemotaxis assay, radioligand competition binding on THP-1 cells and transfected HEK cells\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with mutagenesis, multiple orthogonal assays, highly cited\",\n      \"pmids\": [\"8576227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CCL5/RANTES blocks HIV-1 entry into cells through a pertussis toxin-insensitive mechanism; the V3 domain of gp120 is a critical determinant of susceptibility to CCL5-mediated HIV suppression, linking CCR5 co-receptor usage to chemokine-mediated blocking.\",\n      \"method\": \"HIV infection assay, pertussis toxin treatment, chimeric V3 domain constructs\",\n      \"journal\": \"Nature Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic virology experiments with V3 domain mutants and entry-stage analysis\",\n      \"pmids\": [\"8898753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CCR5 was molecularly cloned as the high-affinity G protein-coupled receptor for CCL5/RANTES, MIP-1β, and MIP-1α on monocytes; receptor activation leads to inositol phosphate generation and calcium flux, both blocked by pertussis toxin, establishing CCR5 as a Gi-coupled receptor for CCL5.\",\n      \"method\": \"cDNA cloning, stable transfection, radioligand binding, calcium flux assay, pertussis toxin treatment\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — receptor cloning with binding and signaling characterization, replicated by multiple groups\",\n      \"pmids\": [\"8663314\", \"8699119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CCL5/RANTES induces a unique biphasic Ca2+ signal in T cells: the first phase is G-protein-mediated and chemotaxis-associated; the second phase (at >100 nM) is tyrosine kinase-linked, correlates with CD3 expression level, and is partially dependent on TCR co-stimulation, indicating a T cell activation pathway distinct from chemotaxis.\",\n      \"method\": \"Ca2+ flux assay, cell sorting by CD3 expression, anti-CD3 pre-stimulation experiments\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional signaling assay with genetic correlation, single lab\",\n      \"pmids\": [\"9552000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CCL5-RANTES fusion antibody retains both CCR5-binding activity and chemoattractant function; the fusion protein induces actin polymerization in THP-1 cells, supports T cell transendothelial migration, and blocks HIV-1 CCR5-mediated entry, demonstrating that the functional domains of CCL5 can be preserved in fusion constructs.\",\n      \"method\": \"Flow cytometry, actin polymerization assay, transendothelial migration assay, HIV infection inhibition assay\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays demonstrating preserved CCL5 activity in fusion format\",\n      \"pmids\": [\"9759898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CCL5/RANTES and other chemokines (SDF-1α, fractalkine) regulate Ca2+ signaling and reduce voltage-dependent Ca2+ currents and excitatory postsynaptic current frequency in hippocampal neurons, and protect neurons from gp120-induced apoptosis, establishing direct chemokine receptor signaling in CNS neurons.\",\n      \"method\": \"Fura-2 Ca imaging, whole-cell patch clamp, RT-PCR for receptor expression, apoptosis assay\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal electrophysiology and imaging methods, functionally validated\",\n      \"pmids\": [\"9826729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"RANTES/CCL5 expression in T lymphocytes is regulated 'late' (3–5 days post-activation) by RFLAT-1, a Krüppel-like family transcription factor whose expression is itself translationally regulated after T cell activation, providing a mechanism for the delayed kinetics of CCL5 expression.\",\n      \"method\": \"Promoter characterization, transcription factor identification, translational regulation assays\",\n      \"journal\": \"Immunological Reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional characterization of a novel transcriptional regulator, single lab with promoter and translational assays\",\n      \"pmids\": [\"11138780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL5/RANTES secreted by thrombin-stimulated platelets is deposited on the surface of inflamed or atherosclerotic endothelium (requiring endothelial activation by IL-1β) and triggers shear-resistant monocyte arrest under flow conditions via RANTES receptors, as blocked by Met-RANTES or anti-RANTES antibody.\",\n      \"method\": \"Parallel-wall flow chamber, ELISA, immunofluorescence, ex vivo carotid artery perfusion, immunohistochemistry in apoE-/- mice\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in vitro and in vivo, mechanistic blockade experiments\",\n      \"pmids\": [\"11282909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL5/RANTES activates Jak2 and Jak3 (pertussis toxin-insensitive), induces tyrosine phosphorylation of CCR5 and Src kinase p56lck (which associates with Jak3), and activates the p38 MAPK pathway (evidenced by p38 and MAPKAP kinase-2 phosphorylation) in CCR5-expressing T cells.\",\n      \"method\": \"Immunoprecipitation, Western blot for phosphorylation, pertussis toxin inhibition, pharmacological p38 inhibition\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple kinase targets identified with Co-IP and pharmacological inhibition, pertussis toxin controls\",\n      \"pmids\": [\"11278738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CCL5/RANTES transcription in alveolar epithelial cells is controlled primarily through an NF-κB cis-element in the promoter after TNF-α stimulation; IFN-γ does not activate transcription but stabilizes RANTES mRNA. TNF-α induces nuclear translocation of IRF-3, but unlike viral infection, TNF-α-induced IRF-3 does not bind the RANTES ISRE, revealing stimulus-specific regulation.\",\n      \"method\": \"Promoter deletion/mutagenesis, luciferase reporter assay, EMSA, nuclear fractionation\",\n      \"journal\": \"American Journal of Physiology - Lung\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — promoter deletion and mutagenesis with multiple orthogonal methods\",\n      \"pmids\": [\"12388374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"H. pylori induces RANTES/CCL5 transcription in gastric epithelial cells through NF-κB activation via IKK and NIK (not through TLR/MyD88 or MEK1 pathways); this requires an intact cag pathogenicity island, as shown by kinase-deficient IKK/NIK mutant transfection.\",\n      \"method\": \"Reporter gene assay, transfection of kinase-deficient mutants, coculture with H. pylori\",\n      \"journal\": \"Infection and Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — dominant-negative mutagenesis with pathway dissection\",\n      \"pmids\": [\"12819056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"17β-estradiol (E2) inhibits NF-κB-dependent CCL5 transcription in keratinocytes by competing with the p65 subunit for limiting amounts of the coactivator CBP/CREB-binding protein, without affecting IκBα degradation or NF-κB DNA binding; both ERα and ERβ mediate this effect.\",\n      \"method\": \"Promoter-luciferase assay, EMSA, immunofluorescence, co-transfection with coactivators/receptor mutants\",\n      \"journal\": \"Journal of Investigative Dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic dissection of transcriptional inhibition with domain mapping, multiple orthogonal assays\",\n      \"pmids\": [\"12603855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCL5 heterophilic interactions with platelet factor 4 (PF4) require structural motifs important for CCL5 higher-order oligomerization (the tetrameric E26A mutant supports PF4 binding but not amplification of monocyte arrest); PF4-RANTES heterodimer formation amplifies RANTES-triggered shear-resistant monocyte arrest on endothelium and involves monocytic chondroitin sulfate.\",\n      \"method\": \"Surface plasmon resonance, ligand blot, flow chamber monocyte adhesion assay, RANTES oligomerization mutants\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biophysical binding measurement plus functional mutagenesis studies\",\n      \"pmids\": [\"15459010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Platelet microparticles (PMPs) contain substantial RANTES/CCL5 and serve as a transcellular delivery system, depositing RANTES on activated endothelium during transient rolling interactions in a flow-dependent manner; PMP-dependent RANTES deposition requires P-selectin, GPIb, GPIIb/IIIa, and JAM-A differentially, and promotes subsequent monocyte arrest.\",\n      \"method\": \"Flow chamber with video microscopy, blocking antibodies, genetic deficiency of PMP adhesion receptors, immunofluorescence\",\n      \"journal\": \"Arteriosclerosis, Thrombosis, and Vascular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with multiple receptor knockouts and flow conditions\",\n      \"pmids\": [\"15890969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL5-induced apoptosis in CCR5-expressing T cells requires: (1) GAG binding on the cell surface (exogenous heparin/chondroitin sulfate or GAG digestion prevents apoptosis; non-GAG-binding mutant 44AANA47-CCL5 does not induce apoptosis); (2) higher-order oligomerization (dimer-forming E66S mutant fails to induce apoptosis; tetramers are the minimal active aggregate); (3) CCR5 tyrosine 339 (CCR5Y339F cells are resistant). The mechanism involves cytochrome c release, caspase-9 and caspase-3 activation.\",\n      \"method\": \"T cell apoptosis assay, GAG digestion, exogenous GAG competition, CCL5 oligomerization mutants, CCR5 tyrosine mutant, caspase activation assays, cytochrome c release\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with mutagenesis of both ligand and receptor, multiple orthogonal readouts\",\n      \"pmids\": [\"16807236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In vivo lung-specific CCL5 overexpression in transgenic mice preferentially induces neutrophil infiltration (rather than eosinophils), and upregulates expression of MIP-2, IP-10, and MCP-1 in the lung, demonstrating a role for CCL5 in neutrophil trafficking.\",\n      \"method\": \"Inducible transgenic mouse model, bronchoalveolar lavage, differential cell counts, RT-PCR\",\n      \"journal\": \"American Journal of Physiology - Lung\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain-of-function in transgenic mice with defined cellular phenotype\",\n      \"pmids\": [\"11000125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL5-evoked Ca2+ elevation in human microglia via CCR5 requires Jak activity, inhibitory G protein (pertussis toxin-sensitive component), PI3K, Btk, and PLC-mediated IP3-dependent Ca2+ release from intracellular stores; the majority of the Ca2+ increase is derived from NAD metabolite-activated sources: cADPR releases Ca2+ from intracellular stores and ADPR evokes Ca2+ influx via nimodipine-sensitive channels.\",\n      \"method\": \"Fura-2 calcium imaging, pharmacological inhibitors (Jak inhibitor, PI3K inhibitor, BTK inhibitor, PLC inhibitor), pertussis toxin, nimodipine\",\n      \"journal\": \"Journal of Neuroscience Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic pharmacological dissection of signaling pathway with multiple inhibitors and calcium imaging\",\n      \"pmids\": [\"16547971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The transcription factor KLF13 (RFLAT-1), together with NF-κB rel proteins p50/p65 and scaffolding proteins, forms a molecular enhancesome at the RANTES promoter in T lymphocytes that recruits chromatin-modifying enzymes (acetylation, methylation, phosphorylation), and KLF13 itself is translationally regulated to control the delayed (3–5 day) RANTES expression after T cell activation.\",\n      \"method\": \"Promoter analysis, transcription factor interaction studies, chromatin modification assays\",\n      \"journal\": \"Nature Clinical Practice Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic complex characterization, though this is a review synthesizing primary findings\",\n      \"pmids\": [\"17322928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"JNK MAPK pathway controls constitutive CCL5 expression in peripheral blood NK cells (unlike delayed expression in T cells) through SP1 binding to a compact promoter region (-75 to -56 bp upstream of TSS), as shown by promoter-reporter assays, EMSA, ChIP, and site-directed mutagenesis of the SP1 binding site.\",\n      \"method\": \"Specific MAPK inhibitors, promoter-reporter assay, EMSA, ChIP, heterologous promoter constructs, site-directed mutagenesis\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods including mutagenesis and ChIP confirming SP1 as the key transcription factor\",\n      \"pmids\": [\"19124744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL5 promotes macrophage survival in human adipose tissue by protecting macrophages from free cholesterol-induced apoptosis via activation of the Akt and Erk pathways, and triggers adhesion and transmigration of blood monocytes through endothelial cells of human adipose tissue.\",\n      \"method\": \"Monocyte transmigration assay, apoptosis assay with free cholesterol, Western blot for Akt/Erk phosphorylation\",\n      \"journal\": \"Arteriosclerosis, Thrombosis, and Vascular Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assays with defined signaling readouts, single lab\",\n      \"pmids\": [\"19893003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Endothelial CCL5 expression, induced by selectin-mediated tumor cell interactions, promotes monocyte recruitment to metastatic tumor cells; CCL5 receptor antagonist treatment during early metastasis reduced tumor cell survival and attenuated metastasis, establishing a mechanistic role for CCL5 in forming the metastatic microenvironment.\",\n      \"method\": \"Microarray, flow chamber monocyte recruitment assay, CCL5 receptor antagonist treatment, in vivo metastasis model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional mechanistic studies in vitro and in vivo with antagonist, single lab\",\n      \"pmids\": [\"19779041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL5 stimulates externalization of S100A4 protein via microparticle shedding from plasma membranes of tumor and stroma cells; conversely, released S100A4 induces fibronectin upregulation in fibroblasts and RANTES upregulation in tumor cells, establishing a positive feedback loop. In vivo, tumor-derived CCL5 promotes S100A4 release into circulation and increases metastatic burden.\",\n      \"method\": \"Microparticle shedding assay, cytokine induction assay, wound healing/migration assay, wild-type vs. S100A4-/- mouse models\",\n      \"journal\": \"PloS One\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic feedback loop established with in vitro and in vivo models\",\n      \"pmids\": [\"20442771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCL5 oligomers form rod-shaped, double-helical polymers; the E66 and E26 mutations that disrupt oligomerization are explained by the structural model. GAG binding by CCL5 oligomers uses a positively charged, fully exposed KKWVR motif (distinct from the partially buried BBXB motif used by monomers/dimers), providing a unified mechanism for how oligomerization and GAG binding cooperate in CCL5 function.\",\n      \"method\": \"NMR residual dipolar couplings, SAXS, hydroxyl radical footprinting, NMR cross-saturation, structural modeling\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — integrated structural approach with multiple orthogonal methods, functional mutant explanation\",\n      \"pmids\": [\"21827949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCL5 promotes osteosarcoma cell migration and upregulates αvβ3 integrin through CCR5 (not CCR1 or CCR3), activating a MEK→ERK→NF-κB signaling cascade; CCR5 mAb, siRNA, and specific inhibitors of MEK, ERK, and NF-κB all abolish CCL5-enhanced migration and integrin upregulation.\",\n      \"method\": \"Migration assay, flow cytometry (integrin expression), siRNA, pharmacological inhibitors, dominant-negative constructs\",\n      \"journal\": \"PloS One\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissection with siRNA and multiple pharmacological inhibitors, single lab\",\n      \"pmids\": [\"22506069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCL5-mediated angiogenesis in vitro and in vivo is dependent on both G protein-coupled receptors CCR1 and CCR5, and on heparan sulfate proteoglycans (syndecan-1, syndecan-4, CD44); chemokine oligomerization and GAG binding are both essential for pro-angiogenic effects, as oligomerization-deficient (E66A) and GAG-binding-deficient (44AANA47) mutants lose angiogenic activity. Pro-angiogenic signaling involves MMP-9 and VEGF secretion by endothelial cells.\",\n      \"method\": \"In vitro endothelial migration/tube formation, rat subcutaneous angiogenesis model, receptor-blocking antibodies, CCL5 oligomerization/GAG mutants, anti-VEGFR antibodies\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with in vitro and in vivo validation, multiple receptor blocking experiments\",\n      \"pmids\": [\"22752444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCL5/CCR5 interaction in chondrosarcoma cells activates PI3K→Akt→NF-κB signaling, leading to upregulation of MMP-3, which mediates increased cell migration; PI3K, Akt, and NF-κB inhibitors and MMP-3 siRNA all block CCL5-induced migration.\",\n      \"method\": \"Migration assay, MMP-3 siRNA/inhibitor, pharmacological inhibitors of PI3K/Akt/NF-κB, Western blot\",\n      \"journal\": \"Biochemical Pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissection with siRNA and multiple inhibitors, single lab\",\n      \"pmids\": [\"19682436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The Fli-1 transcription factor (Ets family member) drives CCL5 transcription by binding to Ets sites in the distal CCL5 promoter; Fli-1 transactivation is stronger than Ets1, and Ets1 acts as a dominant-negative. Systematic deletion of a 225-bp promoter region identifies critical Fli-1 binding sites; mutation of the Fli-1 DNA-binding domain reduces CCL5 promoter transactivation.\",\n      \"method\": \"Fli-1 siRNA knockdown, promoter-reporter assays, ChIP of endogenous Ets binding sites, deletion analysis, DNA-binding domain mutation\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP, mutagenesis, and promoter reporter assays in multiple systems\",\n      \"pmids\": [\"25098295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"YB-1 phosphorylation at Ser-102 (mediated by Akt) increases its binding affinity and trans-activating capacity at the CCL5 promoter during early monocyte/macrophage differentiation; calcineurin (CN) subsequently dephosphorylates YB-1 at Ser-102, preventing CCL5 promoter binding, as demonstrated by Co-IP of YB-1/CN interaction and in vivo cyclosporine A effects on YB-1 phosphorylation status.\",\n      \"method\": \"Co-immunoprecipitation, Western blot for phospho-YB-1, promoter-reporter assay, calcineurin inhibitor (cyclosporine A) in vivo\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — Co-IP plus in vitro and in vivo functional validation with phospho-specific analysis\",\n      \"pmids\": [\"24947514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Computational modeling of the CCL5:CCR5 complex structure reveals that both CCL5 and HIV-1 gp120 V3 loop primarily interact with the same CCR5 residues, providing structural insight into CCL5's mechanism of blocking HIV-1 entry via competitive occupation of the CCR5 binding interface.\",\n      \"method\": \"Computational free energy calculations and molecular dynamics simulations, validated against experimental mutagenesis data\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational prediction; experimental validation is indirect (consistency with published mutational data)\",\n      \"pmids\": [\"24965094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IL-32θ downregulates CCL5 expression by interacting with PKCδ (shown by Co-IP and pulldown assay), facilitating PKCδ-mediated phosphorylation of STAT3 at Ser-727, which prevents STAT3 from binding to and transactivating the CCL5 promoter.\",\n      \"method\": \"Co-immunoprecipitation, pulldown assay, ELISA, promoter binding assay\",\n      \"journal\": \"Cellular Signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP/pulldown with functional promoter analysis, single lab\",\n      \"pmids\": [\"25280942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CCL5 interactions with chondroitin sulfate hexasaccharides involve both the BBXB motif in the 40s loop and residues in the N-loop (similar to receptor N-terminus interactions); the binding orientation is highly dependent on sulfation pattern of N-acetyl galactosamine groups, as shown by paramagnetic relaxation enhancement and NOE NMR constraints.\",\n      \"method\": \"Solution NMR (PRE, NOE), TEMPO-tagged hexasaccharides, structural modeling\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structural determination with multiple constraints, direct identification of binding interface\",\n      \"pmids\": [\"25982530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structures of CCL5 oligomers reveal polymerization as a double-helical rod. The CCL5 oligomer uses a distinct positively charged KKWVR motif for GAG binding (not the BBXB motif which is partially buried), while CCL3 oligomers use a GAG-binding groove formed by residues from two partially buried BBXB motifs. N-terminal conformational changes in CCL3 alter surface properties and dimer-dimer interfaces to affect GAG binding.\",\n      \"method\": \"X-ray crystallography, biophysical analysis\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mechanistic interpretation and structural explanation of mutagenesis data\",\n      \"pmids\": [\"27091995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CCL5 surface presentation on vascular endothelial cells is filamentous and heparan sulfate-dependent; CCL5 mutants restricted in heparin binding, dimerization, or tetramer formation lose filamentous surface organization, appearing granular or undetectable. Filamentous structures persist under flow conditions, suggesting physiological relevance for leukocyte recruitment.\",\n      \"method\": \"Immunofluorescence, electron microscopy, flow conditions, CCL5 oligomerization/GAG-binding mutants\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — electron microscopy structural characterization with multiple mutagenesis controls and flow conditions\",\n      \"pmids\": [\"25791723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ASIC1a activation in rheumatoid arthritis synovial fibroblasts mediates Ca2+ influx, which increases [Ca2+]i and activates NFATc3; nuclear NFATc3 directly binds the RANTES/CCL5 promoter and drives CCL5 gene transcription, as shown by ChIP-qPCR and dual-luciferase reporter assay.\",\n      \"method\": \"Ca2+ imaging, flow cytometry, ChIP-qPCR, dual-luciferase reporter assay, Western blot, immunofluorescence\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct ChIP showing NFATc3 binding to CCL5 promoter combined with reporter assay and calcium signaling mechanistic dissection\",\n      \"pmids\": [\"31903118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL5 secreted by pericytes activates CCR5 on glioblastoma cells, enabling DNA-PKcs-mediated DNA damage repair (DDR) upon temozolomide treatment; genetic pericyte depletion or CCR5 antagonist maraviroc inhibits pericyte-promoted DDR and improves chemotherapeutic efficacy.\",\n      \"method\": \"Pericyte genetic depletion, Co-culture, Western blot for DNA-PKcs activity, GBM xenografts, maraviroc treatment\",\n      \"journal\": \"Cell Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic depletion plus pharmacological inhibition with mechanistic DDR pathway readout, in vivo validation\",\n      \"pmids\": [\"34239070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL5 promotes hippocampal synaptic function and memory by supporting glucose aerobic metabolism, mitochondrial structural integrity, purine synthesis (de novo), and ATP generation; CCL5-knockout mice show impaired hippocampal LTP, reduced synaptic protein expression, and memory deficits reversed by CCL5 re-expression in the hippocampus.\",\n      \"method\": \"CCL5-KO mice, lentiviral CCL5 re-expression, metabolomics, FDG-PET imaging, seahorse metabolic analysis, electron microscopy of mitochondria, electrophysiology (LTP)\",\n      \"journal\": \"Molecular Psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — KO plus rescue, multiple orthogonal metabolic and electrophysiology methods\",\n      \"pmids\": [\"33931731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TTP (tristetraprolin) promotes m6A methylation of CCL5 mRNA (and CCL2 mRNA), which accelerates their degradation; TTP overexpression upregulates m6A methylation enzymes (WTAP, METTL14, YTHDF2) and reduces CCL5 mRNA stability, establishing a novel m6A-dependent RNA decay mechanism for CCL5 regulation.\",\n      \"method\": \"RNA m6A methylation assay, mRNA stability assay, TTP overexpression, m6A methyltransferase expression analysis, in vivo mouse model\",\n      \"journal\": \"JCI Insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic m6A pathway with in vitro and in vivo data, single lab\",\n      \"pmids\": [\"34877932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL5 inhibits influenza A virus replication in alveolar epithelial cells through a PKC-dependent upregulation of the restriction factor SAMHD1; SAMHD1 knockdown abolishes both CCL5-mediated IAV inhibition and CCL5-mediated cell death inhibition.\",\n      \"method\": \"RT-PCR for restriction factor panel, SAMHD1 siRNA knockdown, viral titer assay, PKC inhibitor\",\n      \"journal\": \"Frontiers in Cellular and Infection Microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown with functional viral replication readout and PKC pharmacological dissection\",\n      \"pmids\": [\"34490131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EZH2 promotes CCL5 expression in lung cancer cells; EZH2 knockdown reduces CCL5 and macrophage chemotaxis, while EZH2 overexpression increases CCL5; CCL5 knockdown abolishes EZH2-induced macrophage chemotaxis and cancer cell migration/invasion, placing EZH2 upstream of CCL5 in a pro-metastatic pathway.\",\n      \"method\": \"EZH2 siRNA, CCL5 siRNA, macrophage chemotaxis assay, wound healing, transwell invasion, in vivo xenograft\",\n      \"journal\": \"Biotechnology and Applied Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis by double knockdown, in vitro and in vivo, single lab\",\n      \"pmids\": [\"31855281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HIF-1α transcriptionally activates CCL5 expression by binding the CCL5 promoter; inactivation of Cullin-RING ligases (CRLs) by MLN4924 stabilizes HIF-1α levels, increasing CCL5 which drives M2 macrophage infiltration promoting chronic pancreatitis; CCL5 blockade and macrophage depletion both alleviate pancreatic fibrosis.\",\n      \"method\": \"CRL inactivation (MLN4924), HIF-1α stabilization assay, CCL5 promoter reporter, macrophage depletion, CCL5 blockade, in vivo chronic pancreatitis model\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic HIF-1α→CCL5 axis with promoter data and in vivo models, single lab\",\n      \"pmids\": [\"33723230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Chordoma cells secrete CCL5 to recruit macrophages via CCR5 and promote their M2 polarization; M2 macrophages reciprocally enhance chordoma proliferation, invasion, and migration; CCL5 knockdown or CCR5 antagonist maraviroc inhibits both M2 polarization and malignant progression in organoids and xenograft models.\",\n      \"method\": \"Flow cytometry, multiplex IF, CCL5 knockdown, transwell/chemotaxis assay, patient-derived organoids, xenograft mouse model\",\n      \"journal\": \"Journal for Immunotherapy of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological CCL5/CCR5 blockade with in vitro and in vivo validation\",\n      \"pmids\": [\"37185233\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL5 (RANTES) is a secreted CC chemokine that functions as a selective chemoattractant for memory T cells, monocytes, and eosinophils by binding its principal receptor CCR5 (a Gi-coupled GPCR), triggering pertussis toxin-insensitive Jak2/Jak3 activation, p38 MAPK signaling, and downstream PI3K/Akt/NF-κB pathways; its activity is critically dependent on N-terminal integrity (Met-RANTES is a full antagonist), higher-order oligomerization (tetramers are the minimal active aggregate for apoptosis induction), and GAG/heparan sulfate binding (which mediates filamentous surface presentation on endothelium and concentrates the gradient for leukocyte recruitment); transcription is controlled by NF-κB, KLF13/RFLAT-1, Fli-1, SP1 (in NK cells via constitutive JNK), and NFATc3 (via Ca2+/ASIC1a), with YB-1 phosphorylation/calcineurin-mediated dephosphorylation providing post-translational regulation of promoter activity, and mRNA stability regulated by TTP-mediated m6A methylation-dependent decay.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CCL5 (RANTES) is a CC chemokine that functions as a central mediator of leukocyte recruitment, immune cell activation, tissue fibrosis, angiogenesis, and neuronal metabolic support through signaling via G-protein-coupled receptors CCR1, CCR3, and CCR5. CCL5 assembles into higher-order oligomers whose formation and immobilization on cell-surface and extracellular matrix glycosaminoglycans (via the KKWVR motif) are required for its full biological activities, including shear-resistant monocyte arrest on endothelium, T cell apoptosis through cytochrome c release and caspase-3 activation, and pro-angiogenic signaling [PMID:11282909, PMID:16807236, PMID:27091995, PMID:22752444]. Receptor engagement activates multiple intracellular cascades—Jak2/Jak3–STAT1/STAT3 (pertussis toxin-insensitive), PI3K/Akt, MEK/ERK, p38 MAPK, PLC/Ca²⁺, and Bruton's tyrosine kinase—to drive cell migration, integrin upregulation, MMP expression, and DNA damage repair via DNA-PKcs [PMID:11278738, PMID:16547971, PMID:22506069, PMID:34239070]. CCL5 transcription is cell-type-specifically controlled by an enhancesome containing KLF13 and NF-κB in late-activated T cells, by SP1 via constitutive JNK signaling in NK cells, by Fli-1 in endothelial cells, and by IRF-1 after vascular injury, and is post-transcriptionally regulated through YB-1 phosphorylation/calcineurin-mediated dephosphorylation and TTP-dependent m6A methylation promoting mRNA degradation [PMID:11138780, PMID:19124744, PMID:25098295, PMID:24947514, PMID:34877932].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing that the CCL5 gene has a modular promoter with cell-type-specific activity answered the question of why RANTES expression is restricted to particular hematopoietic lineages.\",\n      \"evidence\": \"Genomic cloning and promoter-luciferase deletion analysis across mature T cell, erythroleukemic, and early progenitor cell lines\",\n      \"pmids\": [\"7689610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific transcription factors responsible for lineage-restricted expression were not identified\", \"Chromatin accessibility and epigenetic regulation not addressed\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrating that TNF-α and IL-1β induce CCL5 in epithelial cells and that dexamethasone inhibits this at the transcriptional level established CCL5 as a cytokine-inducible, glucocorticoid-sensitive inflammatory mediator in non-hematopoietic cells.\",\n      \"evidence\": \"Northern blot, ELISA, mRNA stability assay, and eosinophil chemotaxis assay in A549 lung epithelial cells\",\n      \"pmids\": [\"7537968\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter elements mediating glucocorticoid repression not mapped\", \"Whether dexamethasone acts via GR tethering to NF-κB or direct GRE binding was unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showing that RANTES-induced second-phase Ca²⁺ signaling in T cells depends on TCR/CD3 expression level revealed that CCL5 signaling integrates with the T cell receptor complex, not solely with CCR5.\",\n      \"evidence\": \"Ca²⁺ flux assay in FACS-sorted CD3-high versus CD3-low Jurkat T cells with anti-CD3 pretreatment\",\n      \"pmids\": [\"9552000\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism linking CD3 to CCR5-proximal signaling not defined\", \"Whether physical CCR5–CD3 interaction occurs was not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of KLF13/RFLAT-1 as a translationally regulated transcription factor driving late CCL5 expression in T cells explained the delayed kinetics of RANTES production after T cell activation.\",\n      \"evidence\": \"Transcription factor cloning with promoter assays distinguishing transcriptional versus translational regulation\",\n      \"pmids\": [\"11138780\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Translational regulatory mechanism for KLF13 mRNA not characterized\", \"Cofactor requirements for KLF13 at the CCL5 promoter not yet defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that platelet-derived CCL5 is immobilized on activated endothelium and triggers shear-resistant monocyte arrest established the in vivo mechanism by which CCL5 converts rolling leukocytes to firmly adherent cells during atherogenesis.\",\n      \"evidence\": \"Parallel-wall flow chamber, ELISA, immunofluorescence, ex vivo carotid artery perfusion in ApoE-deficient mice, Met-RANTES blockade\",\n      \"pmids\": [\"11282909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific endothelial GAG species mediating CCL5 immobilization not identified\", \"Stoichiometry of platelet CCL5 deposition in vivo unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Mapping CCL5-induced Jak2/Jak3–STAT1/STAT3 and p38 MAPK signaling downstream of CCR5 in T cells, and showing pertussis toxin insensitivity, revealed a Gαi-independent signaling arm for this chemokine receptor.\",\n      \"evidence\": \"Phospho-specific Western blotting for Jak2, Jak3, STAT1, STAT3, p56lck, p38 MAPK, MAPKAP kinase-2 in PM1 T cells with pertussis toxin and kinase inhibitors\",\n      \"pmids\": [\"11278738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Jak/STAT signaling is direct or requires intermediary adaptors not resolved\", \"Relative contribution of Gαi-dependent versus -independent arms to specific cellular outcomes unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Systematic promoter dissection in epithelial cells showed NF-κB as the dominant cis element for CCL5 transcription, with stimulus-specific usage of ISRE and CRE elements, and IFN-γ acting post-transcriptionally on mRNA stability.\",\n      \"evidence\": \"Promoter deletion/mutagenesis with luciferase reporters, EMSA for NF-κB and IRF-3, mRNA stability assays in A549 cells\",\n      \"pmids\": [\"12388374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ISRE usage during viral versus cytokine stimulation not fully reconciled\", \"Identity of RNA-binding proteins stabilizing CCL5 mRNA in response to IFN-γ unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Establishing that estrogen receptor inhibits CCL5 transcription by competing with NF-κB p65 for limiting CBP coactivator provided a mechanistic basis for sex-hormone-dependent modulation of RANTES-driven inflammation.\",\n      \"evidence\": \"RANTES promoter-luciferase reporter with NF-κB site mutations, EMSA, CBP overexpression rescue in keratinocytes\",\n      \"pmids\": [\"12603855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this CBP competition mechanism operates in vivo at endogenous estrogen levels not tested\", \"Relevance to other NF-κB-dependent chemokines not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defining that CCL5-induced T cell apoptosis requires both oligomerization (≥tetramers) and GAG binding, and proceeds through CCR5 tyrosine 339, cytochrome c release, and caspase-9/3 activation, established the structural and signaling requirements for this cytotoxic function.\",\n      \"evidence\": \"CCR5 mutant receptors (Y339F), CCL5 oligomerization mutants (E66S, E26A), GAG modification assays, caspase activity and cytochrome c release assays\",\n      \"pmids\": [\"16807236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream link between CCR5 Y339 phosphorylation and mitochondrial apoptosis pathway not defined\", \"Whether apoptosis is relevant in vivo during infection or homeostasis unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Dissecting the multi-step CCL5→CCR5 Ca²⁺ signaling cascade in microglia—requiring Jak, Gi, PI3K, Btk, PLC/IP3, and NAD metabolites—revealed an unexpectedly complex pathway integrating kinase and second-messenger systems for chemokine-induced calcium mobilization in the CNS.\",\n      \"evidence\": \"Fura-2 Ca²⁺ imaging with sequential pharmacological blockade in cultured human microglia\",\n      \"pmids\": [\"16547971\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pharmacological inhibitor specificity limits certainty at each step\", \"Functional consequences of this Ca²⁺ signal in microglia not linked to specific microglial behaviors\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identifying SP1 as the transcription factor maintaining constitutive CCL5 expression in NK cells via JNK/MAPK signaling answered how NK cells, unlike T cells, express RANTES without activation.\",\n      \"evidence\": \"JNK/ERK/p38 inhibitors, ChIP, EMSA, SP1 site mutagenesis in peripheral blood NK cells\",\n      \"pmids\": [\"19124744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What maintains constitutive JNK activity in NK cells was not identified\", \"Contribution of SP1 relative to other factors at the NK cell CCL5 promoter not quantified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrating that hematopoietic cell-derived CCL5 directly promotes hepatic stellate cell migration, proliferation, and collagen secretion, and that receptor antagonism reverses fibrosis, established CCL5 as a direct profibrogenic mediator in the liver.\",\n      \"evidence\": \"CCL5 knockout mice, bone marrow transplantation, in vitro stellate cell assays, Met-CCL5 treatment in CCl4 and MCD diet fibrosis models\",\n      \"pmids\": [\"20978355\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific CCL5 receptor (CCR1 vs CCR5) responsible for stellate cell activation not resolved\", \"Whether CCL5 acts directly on collagen gene transcription or indirectly via autocrine loops unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Solving the crystal and solution structures of CCL5 oligomers revealed double-helical rod-shaped assemblies and identified the KKWVR motif (not the BBXB motif) as the primary GAG-binding determinant in the oligomeric context, providing the structural basis for the oligomerization requirement observed functionally.\",\n      \"evidence\": \"X-ray crystallography, NMR residual dipolar couplings, SAXS, hydroxyl radical footprinting of CCL5 oligomers\",\n      \"pmids\": [\"27091995\", \"21827949\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of CCL5 oligomer bound simultaneously to receptor and GAG not determined\", \"Whether the double-helix is the predominant form on cell surfaces in vivo unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linking CCL5/CCR5 signaling to MEK→ERK→NF-κB-dependent αvβ3 integrin upregulation in osteosarcoma and PI3K→Akt→NF-κB-dependent MMP-3 induction in chondrosarcoma expanded the repertoire of CCL5-activated pathways to tumor cell invasion mechanisms.\",\n      \"evidence\": \"Migration assays with specific kinase inhibitors, dominant-negative kinase mutants, siRNA knockdown in tumor cell lines\",\n      \"pmids\": [\"22506069\", \"19682436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether these pathways operate similarly in non-transformed cells not tested\", \"Direct versus indirect NF-κB activation by ERK/Akt in this context not distinguished\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating that CCL5 oligomerization and GAG binding are both required for angiogenic activity (endothelial migration, tube formation, VEGF secretion) through CCR1/CCR5 and syndecan-1/4/CD44 extended the oligomer/GAG paradigm beyond leukocyte recruitment to neovascularization.\",\n      \"evidence\": \"In vitro endothelial assays, in vivo rat angiogenesis model, CCL5 E66A and 44AANA47 mutants, receptor-blocking antibodies\",\n      \"pmids\": [\"22752444\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which syndecan serves as the primary coreceptor in vivo not determined\", \"Mechanism by which GAG-bound CCL5 oligomers trigger VEGF secretion undefined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying Fli-1 as a direct transcriptional activator of CCL5 in endothelial cells, competitively inhibited by Ets1 at shared binding sites, added an endothelial-specific regulatory layer to CCL5 expression.\",\n      \"evidence\": \"ChIP, siRNA knockdown, promoter-luciferase deletion/mutagenesis, dominant-negative Fli-1 in endothelial cells\",\n      \"pmids\": [\"25098295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of Fli-1 for endothelial CCL5 during inflammation not demonstrated\", \"Mechanism of Ets1 dominant-negative effect not fully resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showing that Akt-phosphorylated YB-1 transactivates the CCL5 promoter during monocyte differentiation and that calcineurin dephosphorylates YB-1 to shut down CCL5 expression established a phospho-switch controlling CCL5 at a post-translational/transcriptional interface.\",\n      \"evidence\": \"Reciprocal Co-IP (YB-1/calcineurin), ChIP for YB-1 at CCL5 promoter, phospho-Ser102 immunoblotting, cyclosporine A treatment in vivo\",\n      \"pmids\": [\"24947514\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether YB-1 acts as a direct DNA-binding transcription factor or a cofactor at the CCL5 promoter not distinguished\", \"Calcineurin substrate specificity for YB-1 versus other substrates not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Determining the NMR structure of the CCL5 dimer–chondroitin sulfate complex showed that GAG contacts both the BBXB motif (40s loop) and the N-loop, with sulfation-pattern-dependent orientation, resolving how GAG selectivity is achieved at the dimer level.\",\n      \"evidence\": \"Solution NMR with TEMPO-tagged hexasaccharides, paramagnetic relaxation enhancement, intermolecular NOE in CCL5 dimers\",\n      \"pmids\": [\"25982530\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same contacts persist in larger oligomers not known\", \"In vivo GAG sulfation heterogeneity and its effect on CCL5 presentation not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating that ASIC1a-mediated Ca²⁺ influx activates NFATc3 to directly bind the CCL5 promoter in synovial fibroblasts linked extracellular pH sensing to CCL5-driven joint inflammation.\",\n      \"evidence\": \"Ca²⁺ imaging, ChIP-qPCR for NFATc3 at CCL5 promoter, dual-luciferase reporter, Western blot in RA synovial fibroblasts\",\n      \"pmids\": [\"31903118\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NFATc3 cooperates with NF-κB at the CCL5 promoter in this context not tested\", \"Relevance of ASIC1a→CCL5 axis in other acidic tissue environments unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that pericyte-secreted CCL5 activates CCR5→DNA-PKcs-mediated DNA damage repair in glioblastoma cells, conferring temozolomide resistance reversible by maraviroc, established a non-immune CCL5 function in cancer chemoresistance.\",\n      \"evidence\": \"Co-culture, genetic pericyte depletion, DNA-PKcs phosphorylation, maraviroc treatment in patient-derived xenografts\",\n      \"pmids\": [\"34239070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CCR5 signaling activates DNA-PKcs (direct phosphorylation cascade versus indirect) not defined\", \"Whether this mechanism operates in other tumor types unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that CCL5 supports hippocampal synapse formation and memory through promotion of glycolysis, glutamate/purine metabolism, and mitochondrial ATP generation—with knockout causing LTP and cognitive deficits reversed by re-expression—revealed a metabolic support function for CCL5 in the CNS.\",\n      \"evidence\": \"CCL5 knockout and lentiviral rescue, FDG-PET, metabolomics, Seahorse analysis, electrophysiology, behavioral testing in mice\",\n      \"pmids\": [\"33931731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell type producing and responding to CCL5 in hippocampus (neuron vs glia) not resolved\", \"Whether CCR5 or another receptor mediates the metabolic effects not determined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying TTP-mediated upregulation of m6A methyltransferase components (WTAP, METTL14, YTHDF2) as a mechanism that destabilizes CCL5 mRNA added an epitranscriptomic regulatory layer to CCL5 expression control.\",\n      \"evidence\": \"mRNA stability assays, m6A quantification, TTP overexpression/knockdown in vitro and in mouse acute liver failure model\",\n      \"pmids\": [\"34877932\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether m6A is deposited directly on CCL5 mRNA or acts indirectly not confirmed by site-specific m6A mapping\", \"Mechanism by which TTP upregulates methyltransferase expression unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for simultaneous CCL5 oligomer engagement of both GAGs and the CCR5 receptor, and the signaling mechanism linking CCR5 to DNA-PKcs and to metabolic reprogramming in non-immune cells, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No ternary structure of CCL5 oligomer–GAG–CCR5 exists\", \"Signaling intermediates between CCR5 and DNA-PKcs not identified\", \"Cell-type-specific receptor usage for CCL5's metabolic and neuronal functions not determined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 18, 19, 22, 24, 25]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 6, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 3, 6, 20, 22]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [0, 5, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 22, 23, 27, 32, 33]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 18, 19, 24, 26]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [7, 8, 9, 10, 11, 12, 14]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 23]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CCR5\",\n      \"CCR1\",\n      \"KLF13\",\n      \"YB-1\",\n      \"Fli-1\",\n      \"DNA-PKcs\",\n      \"SAMHD1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CCL5 (RANTES) is a secreted CC-family chemokine that serves as a principal chemoattractant for monocytes, memory T lymphocytes, and eosinophils, and plays broader roles in angiogenesis, neuronal synaptic function, and tumor microenvironment remodeling [PMID:1699135, PMID:1380064, PMID:22752444, PMID:33931731]. CCL5 signals primarily through the Gi-coupled receptor CCR5, activating Jak2/Jak3, p38 MAPK, PI3K/Akt, and NF-κB cascades; its agonist activity is critically dependent on N-terminal integrity, as Met-RANTES acts as a full antagonist [PMID:8663314, PMID:11278738, PMID:8576227]. Higher-order oligomerization into double-helical rod polymers and glycosaminoglycan binding via a surface-exposed KKWVR motif cooperate to enable filamentous presentation on activated endothelium, which is required for shear-resistant leukocyte arrest and apoptosis induction through CCR5 [PMID:27091995, PMID:25791723, PMID:16807236]. Transcription is controlled by NF-κB, KLF13/RFLAT-1 (governing delayed T-cell expression), Fli-1, SP1 (constitutive in NK cells via JNK), NFATc3, and HIF-1α, while post-transcriptionally, TTP promotes m6A-dependent mRNA decay and YB-1 phosphorylation/calcineurin-mediated dephosphorylation modulates promoter occupancy [PMID:12388374, PMID:11138780, PMID:25098295, PMID:19124744, PMID:31903118, PMID:34877932, PMID:24947514].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Identification of CCL5/RANTES as a novel T-cell-specific gene encoding a small secreted cysteine-rich protein established the founding member of a chemokine subfamily and opened investigation into its immune function.\",\n      \"evidence\": \"cDNA library screening, Northern blot, sequence analysis of a T-cell-specific transcript\",\n      \"pmids\": [\"2456327\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No functional activity demonstrated\", \"Receptor unknown\", \"Protein not yet purified\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Demonstrating that recombinant CCL5 selectively attracts monocytes and memory (UCHL1+) T cells but not naive T cells established its chemotactic specificity and defined it as a bona fide chemokine.\",\n      \"evidence\": \"Chemotaxis assay with purified and recombinant RANTES, flow cytometric phenotyping of responding cells\",\n      \"pmids\": [\"1699135\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity unknown\", \"Signaling mechanism uncharacterized\", \"In vivo relevance not yet tested\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Purification of two natural CCL5 forms from platelets (including an O-glycosylated variant) with nanomolar eosinophil chemoattractant potency revealed platelets as a major physiological source and extended the target cell repertoire beyond T cells and monocytes.\",\n      \"evidence\": \"HPLC purification, electrospray mass spectrometry, eosinophil chemotaxis assay from thrombin-stimulated platelet releasates\",\n      \"pmids\": [\"1380064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity still unknown\", \"Significance of O-glycosylation for activity not determined\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"The discovery that CCL5 (with MIP-1α and MIP-1β) constitutes the major HIV-suppressive factor from CD8+ T cells fundamentally linked chemokine biology to HIV pathogenesis and foreshadowed the identification of CCR5 as the HIV co-receptor.\",\n      \"evidence\": \"Protein purification from CD8+ T-cell supernatants, N-terminal sequencing, neutralizing antibody blockade of HIV-1/HIV-2/SIV suppression\",\n      \"pmids\": [\"8525373\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of HIV suppression unknown at this point\", \"Receptor identity not yet confirmed\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Molecular cloning of CCR5 as the Gi-coupled high-affinity receptor for CCL5, combined with the demonstration that Met-RANTES is a full antagonist and that CCL5 blocks HIV entry through CCR5 in a V3-dependent manner, unified the chemotactic and HIV-suppressive activities under a single receptor system and revealed the critical importance of N-terminal integrity for agonism.\",\n      \"evidence\": \"Receptor cloning, radioligand binding, calcium flux with pertussis toxin, E. coli-expressed Met-RANTES in calcium/chemotaxis assays, chimeric V3 domain HIV constructs\",\n      \"pmids\": [\"8663314\", \"8699119\", \"8576227\", \"8898753\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling cascades beyond Gi not characterized\", \"Structural basis of N-terminal activation unknown\", \"Role of oligomerization not addressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Dissection of CCR5 downstream signaling revealed pertussis toxin-insensitive Jak2/Jak3 activation, CCR5 tyrosine phosphorylation, p56lck association with Jak3, and p38 MAPK pathway engagement, distinguishing CCL5/CCR5 signaling from classical Gi-only chemokine cascades; simultaneously, platelet-derived CCL5 was shown to deposit on inflamed endothelium and trigger monocyte arrest under flow.\",\n      \"evidence\": \"Co-IP and phospho-Western blot in T cells with pertussis toxin and p38 inhibitor controls; parallel-wall flow chamber with Met-RANTES blockade and ex vivo carotid perfusion in apoE−/− mice\",\n      \"pmids\": [\"11278738\", \"11282909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural information on CCL5-CCR5 complex\", \"Oligomerization requirements for endothelial deposition not tested\", \"Link between Jak signaling and chemotaxis vs. activation not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Promoter dissection identified NF-κB as the primary transcriptional activator of CCL5 in epithelial cells upon TNF-α stimulation, with IFN-γ acting post-transcriptionally to stabilize mRNA, establishing stimulus-specific regulatory layers.\",\n      \"evidence\": \"Promoter deletion/mutagenesis, luciferase reporter, EMSA, and nuclear fractionation in alveolar epithelial cells\",\n      \"pmids\": [\"12388374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin-level regulation not addressed\", \"mRNA stabilization mechanism undefined\", \"Tissue-specific differences in promoter usage unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Reconstitution experiments with ligand and receptor mutants demonstrated that CCL5-induced T-cell apoptosis requires three cooperating features: GAG binding, higher-order oligomerization (tetramers as the minimal active species), and CCR5 tyrosine-339 phosphorylation, proceeding through the intrinsic apoptotic pathway (cytochrome c/caspase-9/caspase-3).\",\n      \"evidence\": \"GAG-binding mutant 44AANA47, oligomerization mutant E66S, CCR5-Y339F mutant, caspase activation and cytochrome c release assays\",\n      \"pmids\": [\"16807236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for why tetramers are the minimal active species unknown\", \"Signaling intermediates between CCR5-pY339 and mitochondrial apoptosis pathway not identified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Characterization of the KLF13/NF-κB enhancesome at the CCL5 promoter, with KLF13 itself under translational control, provided a molecular explanation for the characteristic 3–5 day delayed CCL5 expression kinetics in activated T cells, distinct from constitutive NK-cell expression driven by JNK→SP1.\",\n      \"evidence\": \"Promoter analysis, transcription factor interaction studies, and chromatin modification assays for T cells; MAPK inhibitors, ChIP, EMSA, and SP1-site mutagenesis for NK cells\",\n      \"pmids\": [\"17322928\", \"19124744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Translational regulatory mechanism for KLF13 not molecularly defined\", \"Whether enhancesome composition differs across T-cell subsets is unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Structural determination of CCL5 oligomers as double-helical rod-shaped polymers, with a fully exposed KKWVR GAG-binding motif distinct from the monomer/dimer BBXB site, provided a unified biophysical framework explaining why oligomerization and GAG binding are jointly required for endothelial surface presentation and leukocyte recruitment.\",\n      \"evidence\": \"NMR, SAXS, hydroxyl radical footprinting, and later X-ray crystallography of CCL5 polymers\",\n      \"pmids\": [\"21827949\", \"27091995\", \"25791723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of the CCL5–CCR5 signaling complex\", \"Dynamics of oligomer assembly/disassembly on endothelial surfaces not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of Fli-1 as a potent CCL5 transcriptional activator via distal Ets promoter sites, and of the Akt-phosphorylated YB-1/calcineurin axis as a post-translational switch controlling CCL5 promoter occupancy during monocyte differentiation, expanded the regulatory network beyond NF-κB and KLF13.\",\n      \"evidence\": \"ChIP, promoter-reporter/deletion analysis, DNA-binding domain mutagenesis for Fli-1; Co-IP of YB-1–calcineurin, phospho-Ser102-specific analysis, cyclosporine A in vivo for YB-1\",\n      \"pmids\": [\"25098295\", \"24947514\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of Fli-1 vs. other Ets factors in different immune cell types unknown\", \"Whether YB-1 phosphorylation integrates with the KLF13 enhancesome is untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Multiple studies revealed expanded functional roles for CCL5: support of hippocampal synaptic plasticity via mitochondrial metabolism and purine synthesis (demonstrated by KO and rescue); TTP-mediated m6A-dependent mRNA decay as a post-transcriptional off-switch; and tumor microenvironment remodeling through CCR5-dependent DNA damage repair in glioblastoma and macrophage M2 polarization in multiple cancers.\",\n      \"evidence\": \"CCL5-KO mice with lentiviral rescue, metabolomics, FDG-PET, and LTP electrophysiology; TTP overexpression with m6A methylation and mRNA stability assays; pericyte depletion/maraviroc in GBM xenografts; CCL5/CCR5 blockade in chordoma organoids and xenografts\",\n      \"pmids\": [\"33931731\", \"34877932\", \"34239070\", \"37185233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor and signaling pathway mediating CCL5's metabolic effects in neurons not identified\", \"Whether TTP-m6A mechanism operates in all CCL5-expressing cell types is unknown\", \"Relative contribution of CCL5 vs. other CCR5 ligands in tumor immune evasion unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution structure of the CCL5–CCR5 signaling complex, the mechanism linking CCR5 Y339 phosphorylation to divergent outcomes (chemotaxis vs. apoptosis), and the identity of the receptor mediating CCL5's neuronal metabolic effects remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No experimental CCL5–CCR5 co-structure\", \"Signaling branch point between chemotaxis, survival, and apoptosis undefined\", \"Neuronal CCL5 receptor and metabolic signaling pathway uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 2, 4, 5, 7, 19]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [12, 17, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 2, 4, 12, 18, 37]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 2, 4, 7, 12, 13, 19, 20, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 8, 13, 21, 24, 28, 30]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [2, 12, 17, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CCR5\",\n      \"CCR1\",\n      \"PF4\",\n      \"KLF13\",\n      \"YB1\",\n      \"NFATc3\",\n      \"FLI1\",\n      \"SP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}